Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission File No. 001-39256

RESEARCH SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)


Nevada	11-3797644
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Address not applicable¹	N/A
(Address of principal executive offices)	(Zip Code)

(310) 477-0354

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:


Title of each Class	Trading Symbol(s)	Name of each Exchange on which registered
Common stock, $0.001 par value	RSSS	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer þ	Smaller reporting company þ
	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ

Indicate the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date.


Title of Class		Number of Shares Outstanding on November 8, 2024
Common Stock, $0.001 par value		32,513,172

¹ In November 2019, we became a fully remote company. Accordingly, we do not currently have principal executive offices.

Table of Contents

TABLE OF CONTENTS

PART I — FINANCIAL INFORMATION	3
Item 1. Condensed Consolidated Financial Statements (unaudited)	3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3. Quantitative and Qualitative Disclosures About Market Risk	33
Item 4. Controls and Procedures	33

PART II — OTHER INFORMATION	34
Item 1A. Risk Factors	34
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	34
Item 6. Exhibits	35

SIGNATURES	36

Table of Contents

PART 1 — FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Balance Sheets


	September 30,
	2024		June 30,
	(unaudited)		2024
Assets
Current assets:
Cash and cash equivalents	$	6,924,773	$	6,100,031
Accounts receivable, net of allowance of $101,949 and $68,579, respectively		6,298,606		6,879,800
Prepaid expenses and other current assets		649,497		643,553
Prepaid royalties		572,524		1,067,237
Total current assets		14,445,400		14,690,621

Non-current assets:
Property and equipment, net of accumulated depreciation of $927,386 and $922,558, respectively		71,659		88,011
Intangible assets, net of accumulated amortization of $1,834,897 and $1,535,310, respectively ($8,117,222 provisional)		10,497,023		10,764,261
Goodwill ($13,171,486 provisional)		16,345,888		16,315,888
Deposits and other assets		915		981
Total assets	$	41,360,885	$	41,859,762

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable and accrued expenses	$	8,257,821	$	8,843,612
Deferred revenue		8,046,056		9,023,848
Total current liabilities		16,303,877		17,867,460

Non-current liabilities:
Contingent earnout liability		12,298,114		12,298,114
Total liabilities		28,601,991		30,165,574

Commitments and contingencies

Stockholders’ equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding		—		—
Common stock; $0.001 par value; 100,000,000 shares authorized; 32,513,172 and 32,295,373 shares issued and outstanding, respectively		32,513		32,295
Additional paid-in capital		38,491,610		38,089,958
Accumulated deficit		(25,640,242)		(26,309,246)
Accumulated other comprehensive loss		(124,987)		(118,819)
Total stockholders’ equity		12,758,894		11,694,188
Total liabilities and stockholders’ equity	$	41,360,885	$	41,859,762

See notes to condensed consolidated financial statements

Table of Contents

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss)

(Unaudited)


	Three Months Ended
	September 30,
	2024		2023

Revenue:
Platforms	$	4,329,645	$	2,600,192
Transactions		7,714,837		7,460,779
Total revenue		12,044,482		10,060,971

Cost of revenue:
Platforms		547,167		382,615
Transactions		5,731,439		5,646,791
Total cost of revenue		6,278,606		6,029,406
Gross profit		5,765,876		4,031,565

Operating expenses:
Selling, general and administrative		4,807,090		5,070,897
Depreciation and amortization		312,095		59,620
Total operating expenses		5,119,185		5,130,517

Income (loss) from operations		646,691		(1,098,952)

Other income		68,525		140,311

Income (loss) from operations before provision for income taxes		715,216		(958,641)
Provision for income taxes		(46,212)		(29,402)

Net income (loss)		669,004		(988,043)

Other comprehensive income (loss):
Foreign currency translation		(6,168)		(946)
Comprehensive income (loss)	$	662,836	$	(988,989)

Basic income (loss) per common share:
Net income (loss) per share	$	0.02	$	(0.04)
Weighted average common shares outstanding		30,346,871		27,052,445

Diluted income (loss) per common share:
Net income (loss) per share	$	0.02	$	(0.04)
Weighted average common shares outstanding		33,234,858		27,052,445

See notes to condensed consolidated financial statements

Table of Contents

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the Three Months Ended September 30, 2024

(Unaudited)


				Additional				Other		Total
	Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Loss		Equity

Balance, July 1, 2024	32,295,373	$	32,295	$	38,089,958	$	(26,309,246)	$	(118,819)	$	11,694,188

Fair value of vested stock options	—		—		28,856		—		—		28,856

Fair value of vested restricted common stock	250,000		250		388,883		—		—		389,133

Forfeited restricted common stock	(48,584)		(48)		48		—		—		—

Repurchase of common stock	(5,757)		(6)		(16,113)		—		—		(16,119)

Common stock issued upon exercise of stock options	22,140		22		(22)		—		—		—

Net income for the period	—		—		—		669,004		—		669,004

Foreign currency translation	—		—		—		—		(6,168)		(6,168)

Balance, September 30, 2024	32,513,172	$	32,513	$	38,491,610	$	(25,640,242)	$	(124,987)	$	12,758,894

See notes to condensed consolidated financial statements

Table of Contents

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Changes in Stockholders’ Equity

For the Three Months Ended September 30, 2023

(Unaudited)


				Additional				Other		Total
	Common Stock			Paid-in		Accumulated		Comprehensive		Stockholders’
	Shares	Amount		Capital		Deficit		Loss		Equity

Balance, July 1, 2023	29,487,508	$	29,487	$	29,941,873	$	(22,522,649)	$	(118,224)	$	7,330,487

Fair value of vested stock options	—		—		17,471		—		—		17,471

Fair value of vested restricted common stock	105,000		105		574,238		—		—		574,343

Repurchase of common stock	(18,603)		(19)		(46,116)		—		—		(46,135)

Common stock issued upon exercise of stock options	50,180		51		(51)		—		—		—

Net loss for the period	—		—		—		(988,043)		—		(988,043)

Foreign currency translation	—		—		—		—		(946)		(946)

Balance, September 30, 2023	29,624,085	$	29,624	$	30,487,415	$	(23,510,692)	$	(119,170)	$	6,887,177

See notes to condensed consolidated financial statements

Table of Contents

Research Solutions, Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

(Unaudited)


	Three Months Ended
	September 30,
	2024		2023

Cash flow from operating activities:
Net income (loss)	$	669,004	$	(988,043)
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization		312,095		59,620
Fair value of vested stock options		28,856		17,471
Fair value of vested restricted common stock		389,133		574,343
Changes in operating assets and liabilities:
Accounts receivable		566,194		(112,965)
Prepaid expenses and other current assets		(5,944)		109,946
Prepaid royalties		494,713		35,140
Accounts payable and accrued expenses		(618,140)		195,747
Deferred revenue		(992,792)		(646,830)
Net cash provided by (used in) operating activities		843,119		(755,571)

Cash flow from investing activities:
Purchase of property and equipment		—		(33,825)
Payment for acquisition of Resolute, net of cash acquired		—		(2,718,253)
Net cash used in investing activities		—		(2,752,078)

Cash flow from financing activities:
Common stock repurchase		(16,119)		(46,135)
Payment of contingent acquisition consideration		—		(110,190)
Net cash used in financing activities		(16,119)		(156,325)

Effect of exchange rate changes		(2,258)		705
Net increase (decrease) in cash and cash equivalents		824,742		(3,663,269)
Cash and cash equivalents, beginning of period		6,100,031		13,545,333
Cash and cash equivalents, end of period	$	6,924,773	$	9,882,064

Supplemental disclosures of cash flow information:
Cash paid for income taxes	$	46,212	$	29,402

Non-cash investing and financing activities:
Contingent consideration accrual on asset acquisition	$	33,353	$	42,989

See notes to condensed consolidated financial statements

Table of Contents

RESEARCH SOLUTIONS, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Three Months Ended September 30, 2024 and 2023 (Unaudited)

Note 1. Organization, Nature of Business and Basis of Presentation

Organization

Research Solutions, Inc. (the “Company,” “Research Solutions,” “we,” “us” or “our”) was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with five wholly owned subsidiaries: Reprints Desk, Inc., (“Reprints Desk”) a Delaware corporation, including its wholly owned subsidiary Resolute Innovation, Inc., a Delaware corporation, Scite, LLC, a Delaware limited liability company, Reprints Desk Latin America S. de R.L. de C.V., an entity organized under the laws of Mexico, and RESSOL LA, S. DE R.L. DE C.V., an entity organized under the laws of Mexico.

Nature of Business

We are a vertical SaaS and artificial intelligence (“AI”) company providing software and related services to help research intensive organizations simplify the research process, save time and money. We offer various software platforms (“Platform” or “Platforms”) that are typically sold to corporate, academic, government and individual researchers as cloud-based software-as-a-service (“SaaS”) via auto-renewing license agreements. Corporate, academic, and government customers typically sign up under annual or multi-year agreements paid annually in advance. Individual researchers can sign up under an annual or a month-to-month agreement and are typically billed monthly. Our Platforms also facilitate the sale of published scientific, technical, and medical (“STM”) content sold as individual articles (“Transactions”) either stand alone or via one or more of the research Platform solutions we provide. When one or more of the Platform solutions are used to purchase Transactions, customers pay for those transactions through monthly billing or via credit card for individual researchers. In addition, our Platforms facilitate rights and permissions for customers to re-use content, ensuring copyright compliance for research, regulatory and marketing use cases as well as the utilization of content with AI applications and for the training of AI models. Our Platforms enable life science and other research-intensive organizations to simplify their research and development activities through our advanced search (i.e. Discovery Tools), tools to access and buy STM articles required to support their research (i.e. Access), as well as tools that manage that content across the enterprise and on an individual basis (i.e. Manage). The Platforms also include advanced AI (“Generative AI”) based assistants to help researchers understand the quality of the articles they are reviewing, speed up the review process, and to more fully understand how various research papers relate to each other. In addition to STM content, the Platforms provide additional context to the research process by including the ability to search and assimilate a variety of other types of data such as Patent, Clinical Trial, Regulatory and Competitive Intelligence data. They also typically deliver a return on investment to the customer by reducing the amount of time it takes a research organization to find, acquire and manage content, in addition to also driving down the ultimate cost per article and overall research costs over time.

Platforms

Our cloud-based SaaS Platforms consist of proprietary software and Internet-based interfaces sold to customers through an annual or monthly subscription fee. Legacy functionality falls into three areas.

Discovery Tools – Our Scite.ai and Resolute.ai solutions facilitate search (discovery) across virtually all STM articles available. These solutions include basic search solutions and advanced search tools. These tools allow for searching and identifying relevant research and then purchasing that research through one of our other solutions. In addition, these tools increasingly enable users to find insights in other datasets adjacent to STM content, such as Clinical Trial, Patent, Life Science & MedTech Regulatory information, Competitor and Technology landscape insights, in addition to searching the customer’s internal datasets. Scite.ai includes full text search capability on most of the worlds STM content providing better search results and citation information as supporting or contrasting evidence. This powers our AI assistant and literature search engine and gives researchers better insights into any topic. The advanced search solutions are sold through a seat, enterprise, or individual license. These Platforms are deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platforms through online web interfaces and via web service APIs that enable

Table of Contents

customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platforms can also be configured to satisfy a customer’s individual preferences. We leverage our Platforms’ efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage.

Access – Our Article Galaxy® (“AG”) and Article Galaxy Scholar (Academic Library version) (“AGS”) solutions allow for research organizations to load their entitlements (subscriptions, discount or token packages, and their existing content library of articles) and AG/AGS manages those entitlements in the background enabling the researchers to focus on acquiring articles they need quickly and efficiently at the lowest possible cost. When used in conjunction with our Discovery Tools Platforms, customers can initiate orders, route orders based on the lowest cost to acquire, obtain spend and usage reporting, automate authentication, and connect seamlessly to in-house and third-party software systems. In addition, Article Galaxy facilitates rights and permissions for various re-use cases, including the utilization in AI applications and training of AI applications, ensuring copyright compliance for our customers.

Manage – Our References solution offers a comprehensive reference management solution with built-in document delivery capabilities specifically designed to meet the collaboration and security needs of research intensive organizations. This user-friendly Platform enables researchers to seamlessly organize their literature, collaborate with team members, and access a vast collection of scientific content. By integrating organization tools with instant access to millions of scholarly articles, our References solution streamlines the research workflow and enhances productivity for scientific professionals.

AI models are integral to powering the unique insights our platforms provide as well as the user experience customers enjoy. Natural language processing (“NLP”) and AI models are used to enhance metadata, define connections between topics and content items as well as to generate data and metrics employed to enable users to rapidly identify and understand the value of content they need for their research. We also use state of the art AI models, such as Large Language Models to include Generative AI “assistants” in several parts of the research workflow today and will continually add capability as we move forward. Today we employ Generative AI technologies as a basis for our recommendation engine in our Discovery Tools, Access, and Manage Platform solutions. In addition, Generative AI based “assistants” in some of our solutions allow the researcher to ask questions about articles, groups of articles (folders), and more. We also have the capability to provide near full text search on STM content in the Scite.ai solution where the publisher gives us the rights to do so. The ability to not only mine an article’s full text but also show snippets of full text is unique to our Company and allows our Generative AI assistants to provide highly accurate results with a very low incidence of hallucinations as part of a Retrieval Augmented Generation framework focused just on STM content. We plan to release several new Platform solutions to enhance the research workflows described above and add new solutions to support the analysis functions that exist in our typical customer base.

Our Platforms are generally deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platforms through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. Our Platforms can also be configured to satisfy a customer’s individual preferences. We leverage our Platforms efficiencies in scalability, stability and development costs to fuel rapid innovation and to gain a competitive advantage.

Table of Contents

Transactions

We provide our researchers with a single source to the universe of published STM content that includes over 200 million existing STM journal articles for instant download, 50 million journal articles for rent, 10 million online book chapters, and 45 million only in print journal articles. In addition, we add between 2 to 4 million newly published STM articles each year. STM content is rented or sold to our customers on a per transaction basis. Researchers and knowledge workers in life science and other research-intensive organizations generally require single copies of published STM journal articles for use in their research activities. These individuals are our primary users and while they typically purchase the articles via one of our Platform solutions, we do have some customers that just order articles from us on behalf of end-users in their organizations.

Core to many of our Platform solutions is providing our customers with ways to find and download digital versions of STM articles that are critical to their research. Customers submit orders for the articles they need which we source and electronically deliver to them generally in under an hour; in most cases in seconds. This service is generally known in the industry as single article delivery or document delivery. We also obtain the necessary permission licenses from the content publisher or other rights holder so that our customer’s use complies with applicable copyright laws and we are expanding these services to include the use of content in AI applications and for the training of AI models. We have arrangements with hundreds of content publishers that allow us to distribute their content. The majority of these publishers provide us with electronic access to their content, which allows us to electronically deliver single articles to our customers often in a matter of seconds. While a vast majority of the articles are available in electronic form, the Company also has workflows to deliver older paper-based articles through relationships we have built with libraries around the world.

Principles of Consolidation

The accompanying financial statements are consolidated and include the accounts of the Company and its wholly-owned subsidiaries. Intercompany balances and transactions have been eliminated in consolidation.

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2024 filed with the SEC. The condensed consolidated balance sheet as of June 30, 2024 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company’s financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. Results of operations for the fiscal periods presented herein are not necessarily indicative of fiscal year-end results.

Note 2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates.

Table of Contents

These estimates and assumptions include estimates for reserves of uncollectible accounts, accruals for potential liabilities, assumptions made in valuing equity instruments issued for services or acquisitions, and realization of deferred tax assets.

Concentration of Credit Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist of cash and cash equivalents and accounts receivable. The Company places its cash with high quality financial institutions and at times may exceed the FDIC $250,000 insurance limit. The Company does not anticipate incurring any losses related to these credit risks. The Company extends credit based on an evaluation of the customer’s financial condition, generally without collateral. Exposure to losses on receivables is principally dependent on each customer’s financial condition. The Company monitors its exposure for credit losses and intends to maintain allowances for anticipated losses, as required.

Cash denominated in Euros and British Pounds with an aggregate US Dollar equivalent of $418,135 and $294,145 at September 30, 2024 and June 30, 2024, respectively, was held by Reprints Desk in accounts at financial institutions located in Europe.

The Company has no customers that represent 10% of revenue or more for the three months ended September 30, 2024 and 2023.

The Company has no customers that accounted for greater than 10% of accounts receivable at September 30, 2024 and June 30, 2024.

The following table summarizes vendor concentrations:


	Three Months Ended
	September 30,
	2024		2023
Vendor A	26	%	24	%
Vendor B	10	%	11	%

Revenue Recognition

The Company accounts for revenue in accordance with Financial Accounting Standard Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company derives its revenues from two sources: annual or monthly licenses that allow customers to access and utilize

Table of Contents

certain premium features of our cloud-based SaaS research intelligence platforms (“Platform” or “Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”).

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

●

identify the contract with a customer;

●

identify the performance obligations in the contract;

●

determine the transaction price;

●

allocate the transaction price to performance obligations in the contract; and

●

recognize revenue as the performance obligation is satisfied.

Platforms

We charge a subscription fee that allows customers to access and utilize certain premium features of our Platforms. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.

Transactions

We charge a transactional service fee for the electronic delivery of single articles, and a corresponding copyright fee for the permitted use of the content. We recognize revenue from single article delivery services upon delivery to the customer provided all other revenue recognition criteria have been met.

Revenue by Geographical Region

The following table summarizes revenue by geographical region:


	Three Months Ended
	September 30,
	2024				2023
United States	$	7,118,728	59.1	%	$	5,861,032	58.3	%
Europe		3,847,411	31.9	%		3,155,709	31.3	%
Rest of World		1,078,343	9.0	%		1,044,230	10.4	%
Total	$	12,044,482	100	%	$	10,060,971	100	%

Table of Contents

Accounts Receivable by Geographical Region

The following table summarizes accounts receivable by geographical region:


	As of September 30, 2024				As of June 30, 2024
United States	$	3,491,224	55.4	%	$	4,125,696	60.0	%
Europe		2,242,100	35.6	%		2,082,900	30.2	%
Rest of World		565,282	9.0	%		671,204	9.8	%
Total	$	6,298,606	100	%	$	6,879,800	100	%

Business Combinations

The Company accounts for its business combinations using the acquisition method of accounting where the purchase consideration is allocated to the tangible and intangible assets acquired, and liabilities assumed, based on their respective fair values as of the acquisition date. The excess of the fair value of the purchase consideration over the estimated fair values of the net assets acquired is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions, especially with respect to intangible assets. Critical estimates in valuing intangible assets include, but are not limited to, expected future cash flows, which includes consideration of future growth and margins, future changes in technology, brand awareness and discount rates. Fair value estimates are based on the assumptions that management believes a market participant would use in pricing the asset or liability.

Intangible Assets

Amortizable finite-lived identifiable intangible assets consist of a developed technology and customer relationships acquired in the acquisition of ResoluteAI effective July 28, 2023 and Scite effective December 1, 2023 (See Note 5), and are stated at cost less accumulated amortization. The developed technology and customer relationships are being amortized over the estimated average useful lives of 3 to 10 years. The Company follows ASC 360 in accounting for finite-lived intangible assets, which requires impairment losses to be recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by the assets are less than the assets’ carrying amounts. As of September 30, 2024, the Company determined there were no indicators of impairment of its intangible assets.

Goodwill

Goodwill consists of the excess of the cost of ResoluteAI and Scite (see Note 5) over the fair value of amounts assigned to assets acquired and liabilities assumed. Under the guidance of ASC 350, goodwill is not amortized, rather it is tested for impairment annually, and will be tested for impairment between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. An impairment loss generally would be recognized when the carrying amount of the reporting unit’s net assets exceeds the estimated fair value of the reporting unit and would be measured as the excess carrying value of goodwill over the derived fair value of goodwill. The Company’s policy is to perform an annual impairment testing for its reporting units on June 30 of each fiscal year.

Deferred Revenue

Contract liabilities, such as deferred revenue, exist where the Company has the obligation to transfer services to a customer for which the entity has received consideration, or when the consideration is due, from the customer.

Cash payments received or due in advance of performance are recorded as deferred revenue. Deferred revenue is primarily comprised of cloud-based software subscriptions which are generally billed in advance. The deferred revenue balance is presented as a current liability on the Company's consolidated balance sheets.

Table of Contents

Cost of Revenue

Platforms

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

Transactions

Cost of Transaction revenue consists primarily of the respective copyright fee for the permitted use of the content, less a discount in most cases, and to a much lesser extent, personnel costs of our operations team and third-party service providers.

Stock-Based Compensation

The Company periodically issues stock options and restricted stock awards to employees and non-employees for services. The Company accounts for such grants issued and vesting based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. The Company recognizes the fair value of stock-based compensation within its Statements of Operations with classification depending on the nature of the services rendered.

Under ASC 718, Repurchase or Cancellation of equity awards, the amount of cash or other assets transferred (or liabilities incurred) to repurchase an equity award shall be charged to equity, to the extent that the amount paid does not exceed the fair value of the equity instruments repurchased at the repurchase date. Any excess of the repurchase price over the fair value of the instruments repurchased shall be recognized as additional compensation cost.

Foreign Currency

The accompanying condensed consolidated financial statements are presented in United States dollars, the functional currency of the Company. Capital accounts of foreign subsidiaries are translated into US Dollars from foreign currency at their historical exchange rates when the capital transactions occurred. Assets and liabilities are translated at the exchange rate as of the balance sheet date. Income and expenditures are translated at the average exchange rate of the period. Although the majority of our revenue and costs are in US dollars, the costs of Reprints Desk Latin America and ResSoL LA are in Mexican Pesos. As a result, currency exchange fluctuations may impact our revenue and the costs of our operations. We currently do not engage in any currency hedging activities.

Gains and losses from foreign currency transactions, which result from a change in exchange rates between the functional currency and the currency in which a foreign currency transaction is denominated, are included in selling, general and administrative expenses and amounted to a gain of $104,240 and a loss of $6,620 for the three months ended September 30, 2024 and 2023, respectively. Cash denominated in Euros and British Pounds with an aggregate US Dollar equivalent of $418,135, and $294,145 at September 30, 2024 and June 30, 2024, respectively, was held in accounts at financial institutions located in Europe.

Table of Contents

The following table summarizes the exchange rates used:


	Three Months Ended		Year Ended
	September 30,		June 30,
	2024	2023	2024	2023
Period end Euro : US Dollar exchange rate	1.12	1.06	1.07	1.09
Average period Euro : US Dollar exchange rate	1.09	1.10	1.08	1.05

Period end GBP : US Dollar exchange rate	1.34	1.22	1.26	1.27
Average period GBP : US Dollar exchange rate	1.29	1.28	1.26	1.20

Period end Mexican Peso : US Dollar exchange rate	0.05	0.06	0.05	0.06
Average period Mexican Peso : US Dollar exchange rate	0.05	0.06	0.06	0.05

Net Income (Loss) Per Share

Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding for the period, excluding shares of unvested restricted common stock. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Diluted earnings per share is computed by dividing the net income applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Shares of restricted stock are included in the diluted weighted average number of common shares outstanding from the date they are granted. Potential common shares are excluded from the computation when their effect is antidilutive. Basic and diluted net loss per common share is the same for the three months ended September 30, 2023 because all stock options, warrants, and unvested restricted common stock are anti-dilutive.

The following table reconciles the numerators and denominators used in the computations of both basic and diluted earnings per share:


	Three Months Ended
	September 30,
	2024		2023

Net income (loss) available to common shareholders	$	669,004	$	(988,043)

Weighted average commons shares - basic		30,346,871		27,052,445
Dilutive effect of outstanding warrants and stock options		810,481		—
Dilutive effect of unvested restricted common stock		2,077,506		—
Weighted average commons shares - diluted		33,234,858		27,052,445

Net income (loss) per common share:
Basic	$	0.02	$	(0.04)
Diluted	$	0.02	$	(0.04)

Fair Value of Financial Instruments

Accounting standards require certain assets and liabilities to be reported at fair value in the financial statements and provide a framework for establishing that fair value. Fair value is defined as the price at which an asset could be exchanged or a liability transferred in a transaction between knowledgeable, willing parties in the principal or most advantageous market for the asset or liability. Where available, fair value is based on observable market prices or parameters or derived from such prices or parameters. Where observable prices or parameters are not available, valuation models are applied. A fair value hierarchy prioritizes the inputs used in measuring fair value into three broad levels as follows:

Table of Contents

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

Level 3 – Unobservable inputs based on the Company’s assumptions.

The Company is required to use observable market data if such data is available without undue cost and effort.

The carrying amounts of financial assets and liabilities, such as cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values because of the short maturity of these instruments.

Recently Issued Accounting Pronouncements

In November 2023, the FASB amended ASC No. 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures,” that includes requirements for interim segment disclosures and for entities operating under a single segment. The amendment is effective on a retrospective basis for fiscal years beginning after December 15, 2023 and interim periods beginning after January 1, 2025 with early adoption permitted. The Company is currently assessing the impact of the adoption of ASU 2023-07 on its interim and annual disclosures.

In December 2023, the FASB amended ASC 740, Income Taxes (issued under Accounting Standards Update (ASU) 2023-09, “Improvements to Income Tax Disclosures”). This ASU requires additional disclosures related to the rate reconciliation, income taxes paid and other amendments intended to enhance effectiveness and comparability. The amendment is effective for the Company beginning with its fiscal year 2025 annual disclosures. The Company is currently evaluating the impact of the adoption of ASU 2023-09 on its annual disclosures.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Note 3. Line of Credit

On April 15, 2024, the Company entered into a Loan Agreement (the “PNC Loan Agreement”) with PNC Bank, National Association (“PNC”), as lender. Pursuant to the PNC Loan Agreement, the Company entered into a Revolving Line of Credit Note (the “PNC Note”) with PNC, which provides for a $500,000 secured revolving line of credit that matures on April 15, 2025 and bears interest annually at the daily SOFR rate plus 2.5%, with accrued interest due and payable monthly. The PNC Note contains customary events of default including, among other things, payment defaults, material misrepresentations, breaches of covenants, revocation of guarantee, certain bankruptcy and insolvency events. There were no outstanding borrowings under the line of credit as of September 30, 2024.

Note 4. Stockholders’ Equity

Stock Options

In December 2007, we established the 2007 Equity Compensation Plan (the “2007 Plan”) and in November 2017 we established the 2017 Omnibus Incentive Plan (the “2017 Plan”), collectively (the “Plans”). The Plans were approved by our board of directors and stockholders. The purpose of the Plans is to grant stock and options to purchase our common stock, and other incentive awards, to our employees, directors and key consultants. On November 10, 2016, the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2007 Plan increased from 5,000,000 to 7,000,000. On November 21, 2017, the Company’s stockholders approved the adoption of the 2017 Plan (previously adopted by our board of directors on September 14, 2017), which authorized a maximum of 1,874,513 shares of common stock that may be issued pursuant to awards granted under the 2017 Plan. On November 17, 2020, the Company's stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 2,374,513 to 3,374,513. On November 17, 2021, the Company's stockholders approved an increase in the maximum number of shares of common stock that may be issued pursuant to awards granted under the 2017 Omnibus Incentive Plan from 3,374,513 to 6,874,513. Upon adoption of the 2017 Plan we ceased granting incentive awards under the 2007 Plan and commenced granting incentive awards under the

Table of Contents

2017 Plan. The shares of our common stock underlying cancelled and forfeited awards issued under the 2017 Plan may again become available for grant under the 2017 Plan. Cancelled and forfeited awards issued under the 2007 Plan that were cancelled or forfeited prior to November 21, 2017 became available for grant under the 2007 Plan. As of September 30, 2024, there were 836,577 shares available for grant under the 2017 Plan, and no shares were available for grant under the 2007 Plan. All incentive stock award grants prior to the adoption of the 2017 Plan on November 21, 2017 were made under the 2007 Plan, and all incentive stock award grants after the adoption of the 2017 Plan on November 21, 2017 were made under the 2017 Plan.

The majority of awards issued under the Plan vest immediately or over three years, with a one-year cliff vesting period and have a term of ten years. Stock-based compensation cost is measured at the grant date, based on the fair value of the awards that are ultimately expected to vest, and recognized on a straight-line basis over the requisite service period, which is generally the vesting period.

The following table summarizes vested and unvested stock option activity:


	All Options			Vested Options			Unvested Options
		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at June 30, 2024	2,788,625	$	1.93	2,529,856	$	1.85	258,769	$	2.73
Granted	—		—	—		—	—		—
Options vesting	—		—	417		2.19	(417)		2.19
Exercised	(74,321)		1.92	(74,321)		1.92	—		—
Forfeited	—		—	—		—	—		—
Outstanding at September 30, 2024	2,714,304	$	1.93	2,455,952	$	1.84	258,352	$	2.73

The weighted average remaining contractual life of all options outstanding as of September 30, 2024 was 4.84 years. The remaining contractual life for options vested and exercisable at September 30, 2024 was 4.38 years. Furthermore, the aggregate intrinsic value of options outstanding as of September 30, 2024 was $2,269,490, and the aggregate intrinsic value of options vested and exercisable as of September 30, 2024 was $2,269,265, in each case based on the fair value of the Company’s common stock on September 30, 2024.

During the three months ended September 30, 2024, the Company did not grant any options to employees. The total fair value of options that vested during the three months ended September 30, 2024 was $28,856 and is included in selling, general and administrative expenses in the accompanying statement of operations. As of September 30, 2024, the amount of unvested compensation related to stock options was $227,465 which will be recorded as an expense in future periods as the options vest. During the three months ended September 30, 2024, the Company issued 22,140 net shares of common stock upon the exercise of options underlying 74,321 shares of common stock.

Table of Contents

The following table presents the information regarding stock options outstanding and exercisable as of September 30, 2024:


	Option		Remaining
	Exercise	Options	Contractual	Options
	Price	Outstanding	Life (in years)	Exercisable
$	0.70	225,000	1.18	225,000
	0.80	16,000	0.89	16,000
	0.90	15,000	0.84	15,000
	1.00	15,000	0.44	15,000
	1.05	305,000	1.90	305,000
	1.09	40,000	1.65	40,000
	1.10	105,000	0.75	105,000
	1.20	247,000	3.14	247,000
	1.59	25,000	3.61	25,000
	2.10	238,767	7.36	238,767
	2.13	211,500	6.13	211,500
	2.15	200,000	8.19	200,000
	2.17	28,000	6.61	28,000
	2.19	5,000	7.30	4,582
	2.40	284,000	4.12	284,000
	2.43	61,250	6.68	61,250
	2.45	89,500	5.84	89,500
	2.49	73,000	5.61	73,000
	2.50	20,000	4.63	20,000
	2.64	7,353	6.85	7,353
	2.67	21,000	6.96	21,000
	2.73	257,934	9.19	—
	2.99	8,000	5.62	8,000
	3.13	208,000	5.12	208,000
	3.50	8,000	5.37	8,000
	Total	2,714,304		2,455,952

Restricted Common Stock

Prior to July 1, 2024, the Company issued 5,589,592 shares of restricted common stock to employees valued at $8,429,086, of which 3,152,377 shares have vested, 479,489 shares with fair value of $580,156 have been forfeited, and $6,473,731 has been recognized as an expense. The balance of the non-vested shares of restricted common stock was 1,957,726 at June 30, 2024, with an aggregate fair value of $1,375,199.

During the three months ended September 30, 2024, the Company issued an additional 250,000 shares of restricted stock to an employee with an aggregate fair value of $532,000. The shares were granted, under the 2017 Plan, as restricted stock awards to key management in accordance with its long-term equity bonus program (the “LTEBP”). The LTEBP replaces the previous restricted stock compensation program for executives. It spans 5 years and is designed to better serve stockholder interests by aligning key executive compensation with stockholder value. Awards under the LTEBP will vest as follows, upon the 30-day volume weighted average price (VWAP) of our common stock reaching the following targets:

•20% at a 30-day VWAP of $3.00 per share (this vesting occurred on March 14, 2024);

•20% at a 30-day VWAP of $3.75 per share;

•20% at a 30-day VWAP of $4.50 per share;

•20% at a 30-day VWAP of $5.25 per share; and

•20% at a 30-day VWAP of $6.00 per share.

Table of Contents

Upon a change of control, vesting will accelerate with respect to that portion of the award that would vest if the target 30-day VWAP was achieved at the level above the per share price in such change of control transaction. For example, if we granted an award of 100,000 shares under the LTEBP, 20,000 shares would vest upon our stock price achieving a 30-day VWAP of $3.00 per share, and 20,000 shares would vest upon our stock price achieving a 30-day VWAP of $3.75 per share. If the per share price in a change of control transaction was $5.00 per share, vesting would accelerate for 40,000 shares under the same award (i.e. the number of shares that would vest for our stock price achieving a 30-day VWAP of $5.25 per share, pursuant to a tier round up provision in the Plan effective upon a change in control). As a condition to receiving awards under the LTEBP, recipients will be required to hold at least 75% of all vested shares during the term of their employment. Applicable target 30-day VWAPs must be achieved within 5 years following the grant of awards under the LTEBP, and all unvested awards under the LTEBP will be forfeited upon expiration of such 5-year period. Recipients will also forfeit unvested awards in the event their service with our company terminates for any reason.

As the vesting of the 250,000 shares of restricted common stock under the LTEBP is subject to certain market conditions, pursuant to current accounting guidelines, the Company determined the fair value, with the assistance of a valuation specialist, to be $532,000, computed using the Monte Carlo simulations on a binomial model with a derived service period ranging from 0.75 to 2.33 years. The total fair value of restricted common stock vesting and expenses related to amortization of the fair value of the LTEBP program during the three months ended September 30, 2024 was $389,133 and is included in selling, general and administrative expenses in the accompanying statements of operations. As of September 30, 2024, the amount of unvested compensation related to issuances of restricted common stock was $1,421,141, which will be recognized as an expense in future periods as the shares vest. When calculating basic net income per share, these shares are included in weighted average common shares outstanding from the time they vest. When calculating diluted net income per share, these shares are included in weighted average common shares outstanding as of their grant date. When calculating net loss per share, the 2,129,523 shares are considered antidilutive and are excluded from that calculation.

The following table summarizes restricted common stock activity:


				Weighted
				Average
	Number of			Grant Date
	Shares	Fair Value		Fair Value
Non-vested, June 30, 2024	1,957,726	$	1,375,199	$	1.63
Granted	250,000		532,000		2.13
Vested	(29,619)		(389,133)		2.14
Forfeited	(48,584)		(96,925)		2.18
Non-vested, September 30, 2024	2,129,523	$	1,421,141	$	1.67

Common Stock Repurchases

Effective as of March 19, 2024, the Compensation Committee of our Board of Directors authorized the repurchase, on the last day of each trading window during which the outstanding awards remain outstanding and otherwise in accordance with our insider trading policies, of an aggregate value not exceeding $750,000, in addition to the prior remaining balance of outstanding common stock of $82,347 (at prices no greater than $4.00 per share) from our employees to satisfy their tax obligations in connection with the vesting of stock incentive awards through the end of fiscal year 2025. The actual number of shares repurchased will be determined by applicable employees in their discretion and will depend on their evaluation of market conditions and other factors. As of June 30, 2024, $346,893 remained under the current authorization to repurchase our outstanding common stock from our employees.

During the three months ended September 30, 2024, the Company repurchased 5,757 shares of our common stock from employees at an average market price of approximately $2.80 per share for an aggregate amount of $16,119. As of September 30, 2024, $330,774 remains under the current authorization to repurchase our outstanding common stock from our employees.

Shares repurchased are retired and deducted from common stock for par value and from additional paid in capital for the excess over par value. Direct costs incurred to acquire the shares are included in the total cost of the shares.

Table of Contents

Note 5. Acquisitions

FIZ

On September 28, 2022, Reprints Desk entered into an asset purchase agreement with FIZ Karlsruhe – Leibniz-Institut für Informationsinfrastruktur GmbH (“FIZ”). FIZ delivers STM content pursuant to various contracts with its customers through its AutoDoc platform. FIZ agreed to assign and transfer to Reprints Desk certain of these contracts effective January 1, 2023 (the “Sold Contracts”).

On September 30, 2022, Reprints Desk made a non-refundable payment of $297,450 (€300,000) (the “Base Amount”) as initial consideration for the asset purchase. As of September 30, 2024, Reprints Desk has paid $64,578 in contingent consideration for customers that have their Sold Contracts assumed by Reprints Desk in comparison to the trailing twelve months of revenue of all Sold Contracts (the “Base Amount Plus”). As of September 30, 2024, $33,353 in contingent consideration was recorded for customers that placed an order and have consented to have their contract assumed by Reprints Desk (the “Bonus Amount”). As of September 30, 2024, $31,018 of Bonus Amount payments were made for the 2025 fiscal year and 2024. The Bonus Amount is based upon the collectable service fee that FIZ would have received from these customers. Contingent consideration for the Bonus Amount will continue to be paid in arrears through the quarter ending December 31, 2025.

The current contingent consideration for the Base Amount Plus and the Bonus Amount is recorded as a short-term liability on the balance sheet. At September 30, 2024, the Base Amount, the Base Amount Plus and the Bonus Amount were recorded as intangible assets on the balance sheet with an estimated average useful life of 10 years.

ResoluteAI

On July 28, 2023, the Company acquired 100% of the outstanding stock of Resolute Innovation, Inc. (“ResoluteAI”), a Delaware corporation, an advanced search platform that equips organizations with search, discovery and knowledge management tools that are powered by artificial intelligence (“AI”) and NLP technologies. The total purchase consideration for ResoluteAI, net of cash acquired, was approximately $4.7 million. The consideration included an initial payment of $2.8 million, a holdback of $0.1 million and a contingent earnout that had an initial fair value of $1.8 million. The Company’s revaluation of the earnout resulted in a fair value of $0 as of September 30, 2024. The contingent earnout payment will be based upon the product of three and one half multiplied by ending annual recurring revenue as of January 31, 2025 less the agreed upon Enterprise Value of $3.4 million.

Scite

On December 1, 2023, the Company acquired 100% of the outstanding stock of Scite, Inc. a Delaware corporation (“Scite”), a platform for discovering and evaluating scientific articles via an AI model to create unique “Smart Citations”. Smart Citations allow users to see how a publication has been cited by providing the context of the citation and a classification describing whether it allows for supporting or contrasting evidence for the cited claim.

The total purchase consideration for Scite, net of cash acquired, was approximately $21.1 million. The consideration included an initial payment of $7.2 million in cash, $6.5 million in stock, a holdback of $0.2 million and a contingent earnout that had an initial fair value of $7.2 million. The Company’s revaluation of the earnout resulted in a fair value of $12.2 million as of September 30, 2024.

Table of Contents

The following sets out the unaudited pro forma operating results for the three months ended September 30, 2024 and 2023 for the Company had the Scite acquisition occurred as of July 1, 2023. These amounts include amortization of intangible assets:


	Pro Forma (Unaudited)
	Three Months ended September 30,
	2024		2023

Revenue	$	12,044,482	$	10,800,908
Cost of revenue		6,278,606		6,090,058
Gross profit		5,765,876		4,710,850

Total operating expenses		5,119,185		5,673,375

Loss from operations		646,691		(962,525)

Other income (expense)		68,525		141,313

Income (loss) from operations before provision for income taxes		715,216		(821,212)
Provision for income taxes		(46,212)		(29,402)

Pro Forma Net income (loss)	$	669,004	$	(850,614)
Pro Forma Net income (loss) per weighted average share, basic	$	0.02	$	(0.03)
Pro Forma Net income (loss) per weighted average share, diluted	$	0.02	$	(0.03)

The Company utilized the acquisition method of accounting for the acquisition in accordance with ASC 805, Business Combinations, and allocated the purchase price to ResoluteAI’s and Scite’s tangible assets, identifiable intangible assets, and assumed liabilities at their estimated fair values as of the date of acquisition. The fair value assigned to the developed technology and customer relationships were determined using the multi-period excess earnings method, which estimates the direct cash flow expected to be generated from the existing customers acquired. The cash flows were based on estimates used to value the acquisition, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model, as well as the weighted average cost of capital.

The valuation assumptions took into consideration the Company’s estimates of customer attrition and revenue growth projections. The excess of the purchase price paid by the Company over the estimated fair value of identified tangible and intangible assets has been recorded as goodwill. Goodwill also represents the future benefits as a result of the acquisitions that the Company believes will enhance the Company’s product offerings and lineup available to both new and existing customers and generate future synergies within the software and related services business.

At the date of the acquisition and as of this Quarterly Report on Form 10-Q, management has not yet finalized its valuation analysis related to Scite acquisition. The fair values of the assets acquired, as set forth below, are considered provisional and subject to adjustment as additional information is obtained through the purchase price measurement period (a period of up to one year from the closing date). Any prospective adjustments through the purchase price measurement period would change the fair value allocation as of the acquisition date. The Company is still in the process of reviewing underlying models, assumptions and discount rates used in the valuation of provisional goodwill and intangible assets.

Table of Contents

The following table represents the Company’s allocation of the total purchase consideration to the fair value of tangible assets, identifiable intangible assets, and assumed liabilities of ResoluteAI and Scite on the date of acquisition:


In thousands	ResoluteAI		Scite
Fair value of consideration
Cash	$	2,774	$	7,217
Holdback cash paid		125		175
Common Stock (2,729,014 shares at $2.40 per share)		—		6,549
Contingent earn-out		1,867		7,194
Total purchase price		4,766		21,135

Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Cash and cash equivalents		59		—
Accounts receivable		162		109
Prepaid expenses		43		—
Accounts payable and accrued expenses		(33)		—
Deferred revenue		(649)		(997)
Other current liabilities		(60)		(18)
Net tangible assets		(478)		(906)

Intangible assets:
Developed technology		2,000		8,800
Customer relationships		100		70
Net identifiable intangible assets		2,100		8,870

Goodwill		3,144		13,171

Fair value of net assets acquired	$	4,766	$	21,135

Note 6. Contingencies

Inflation Risk

The Company does not believe that inflation has had a material effect on its operations to date, other than its impact on the general economy. However, there is a risk that the Company’s operating costs could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing the Company’s operating costs, and which would put additional stress on the Company’s working capital resources.

Note 7. Subsequent Events

On November 12, 2024, the Company granted 340,000 shares of restricted common stock to an employee under the long-term equity bonus plan, or LTEBP.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Notice Regarding Forward-Looking Statements

The following discussion and analysis of our financial condition and results of operations for the three months ended September 30, 2024 and 2023 should be read in conjunction with our consolidated financial statements and related notes to those financial statements that are included elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risks and uncertainties, such as our plans, objectives, expectations, and intentions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2024.

We use words such as “anticipate,” “estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,” “believe,” “intend,” “may,” “will,” “should,” “could,” and similar expressions to identify forward-looking statements. All forward-looking statements included in this report are based on information available to us on the date hereof and, except as required by law, we assume no obligation to update any such forward-looking statements.

Overview

Research Solutions was incorporated in the State of Nevada on November 2, 2006, and is a publicly traded holding company with five wholly owned subsidiaries as of September 30, 2024: Reprints Desk, Inc., a Delaware corporation, including its wholly owned subsidiary Resolute Innovation, Inc., a Delaware corporation, Scite, LLC, a Delaware limited liability company, Reprints Desk Latin America S. de R.L. de C.V., an entity organized under the laws of Mexico, and RESSOL LA, S. DE R.L. DE C.V., an entity organized under the laws of Mexico.

Platforms

Table of Contents

allow for searching and identifying relevant research and then purchasing that research through one of our other solutions. In addition, these tools increasingly enable users to find insights in other datasets adjacent to STM content, such as Clinical Trial, Patent, Life Science & MedTech Regulatory information, Competitor and Technology landscape insights, in addition to searching the customer’s internal datasets. Scite.ai includes full text search capability on most of the worlds STM content providing better search results and citation information as supporting or contrasting evidence. This powers our AI assistant and literature search engine and gives researchers better insights into any topic. The advanced search solutions are sold through a seat, enterprise, or individual license. These Platforms are deployed as a single, multi-tenant system across our entire customer base. Customers securely access the Platforms through online web interfaces and via web service APIs that enable customers to leverage Platform features and functionality from within in-house and third-party software systems. The Platforms can also be configured to satisfy a customer’s individual preferences. We leverage our Platforms’ efficiencies in scalability, stability and development costs to fuel rapid innovation and competitive advantage.

Table of Contents

Transactions

Inflation Risk

We do not believe that inflation has had a material effect on its operations to date, other than its impact on the general economy. However, there is a risk that our operating costs could become subject to inflationary and interest rate pressures in the future, which would have the effect of increasing our operating costs, and which would put additional stress on our working capital resources.

Critical Accounting Policies and Estimates

The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosure of contingent assets and liabilities. When making these estimates and assumptions, we consider our historical experience, our knowledge of economic and market factors and various other factors that we believe to be reasonable under the circumstances. Actual results may differ under different estimates and assumptions.

The accounting estimates and assumptions discussed in this section are those that we consider to be the most critical to an understanding of our financial statements because they inherently involve significant judgments and uncertainties.

Revenue Recognition

We account for revenue in accordance with ASU 2014-09, Revenue from Contracts with Customers (Topic 606), (“ASC 606”). The underlying principle of ASC 606 is to recognize revenue to depict the transfer of goods or services to customers at the amount expected to be collected.

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that we expect to receive in exchange for those goods or services. We derive our revenues from two sources: annual or monthly licenses that allow customers to access and utilize certain premium features of our cloud-based SaaS research intelligence platforms (“Platform” or “Platforms”) and the transactional sale of STM content managed, sourced and delivered through the Platform (“Transactions”).

Table of Contents

We apply the following five steps in order to determine the appropriate amount of revenue to be recognized as we fulfill our obligations under each of our agreements:

●

identify the contract with a customer;

●

identify the performance obligations in the contract;

●

determine the transaction price;

●

allocate the transaction price to performance obligations in the contract; and

●

recognize revenue as the performance obligation is satisfied.

Platforms

Transactions

Stock-Based Compensation

The fair value of our stock options is estimated using the Black-Scholes-Merton Option Pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the stock options or restricted stock, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes-Merton Option Pricing model and based on actual experience. The assumptions used in the Black-Scholes-Merton Option Pricing model could materially affect compensation expense recorded in future periods.

Recently Issued Accounting Pronouncements

Please refer to footnote 2 to the condensed consolidated financial statements contained elsewhere in this Form 10-Q for a discussion of Recently Issued Accounting Pronouncements.

Table of Contents

Quarterly Information (Unaudited)

The following table sets forth unaudited and quarterly financial data for the most recent eight quarters:


	Sept. 30,		June 30,		Mar. 31,		Dec. 31,		Sept. 30,		June 30,		Mar. 31,		Dec. 31,
	2024		2024		2024		2023		2023		2023		2023		2022
Revenue:
Platforms	$	4,329,645	$	4,277,338	$	3,953,403	$	3,125,584	$	2,600,192	$	2,303,375	$	2,249,632	$	2,110,272
Transactions		7,714,837		7,856,176		8,162,269		7,188,158		7,460,779		7,656,342		8,092,794		6,606,394
Total revenue		12,044,482		12,133,514		12,115,672		10,313,742		10,060,971		9,959,717		10,342,426		8,716,666

Cost of revenue:
Platforms		547,167		627,051		571,352		486,185		382,615		275,110		268,630		253,073
Transactions		5,731,439		5,863,596		6,062,388		5,343,755		5,646,791		5,764,064		6,046,523		5,059,766
Total cost of revenue		6,278,606		6,490,647		6,633,740		5,829,940		6,029,406		6,039,174		6,315,153		5,312,839

Gross profit:
Platforms		3,782,478		3,650,287		3,382,051		2,639,399		2,217,577		2,028,265		1,981,002		1,857,199
Transactions		1,983,398		1,992,580		2,099,881		1,844,403		1,813,988		1,892,278		2,046,271		1,546,628
Total gross profit		5,765,876		5,642,867		5,481,932		4,483,802		4,031,565		3,920,543		4,027,273		3,403,827

Operating expenses:
Sales and marketing		1,190,407		830,195		1,122,365		804,927		685,016		455,030		642,624		666,608
Technology and product dev.		1,372,758		1,489,491		1,371,754		1,336,558		1,244,579		991,093		953,677		922,132
General and administrative		1,930,176		1,917,908		2,027,073		2,023,848		2,542,868		1,649,333		1,871,590		1,613,664
Depreciation and amortization		312,095		311,004		309,898		155,749		59,620		22,163		18,332		6,342
Stock-based comp. expense		417,989		426,190		541,002		596,455		591,814		585,384		480,458		608,703
Foreign currency transaction loss (gain)		(104,240)		6,336		22,177		(13,738)		6,620		(37,743)		(72,547)		(84,179)
Total operating expenses		5,119,185		4,981,124		5,394,269		4,903,799		5,130,517		3,665,260		3,894,134		3,733,270
Other income (expenses and income taxes)		22,313		(3,482,970)		(11,362)		366,369		110,909		120,463		103,703		73,913
Net income (loss)	$	669,004	$	(2,821,227)	$	76,301	$	(53,628)	$	(988,043)	$	375,746	$	236,842	$	(255,530)

Basic income (loss) per common share:
Net income (loss) per share	$	0.02	$	(0.09)	$	-	$	-	$	(0.04)	$	0.01	$	0.01	$	(0.01)
Basic weighted average common shares outstanding		30,346,871		30,314,522		30,020,652		28,092,945		27,052,445		26,981,813		26,929,314		26,816,550

Diluted income (loss) per common share:
Net income (loss) per share	$	0.02	$	(0.09)	$	-	$	-	$	(0.04)	$	0.01	$	0.01	$	(0.01)
Diluted weighted average common shares outstanding		33,234,858		30,314,522		33,511,242		28,092,945		27,052,445		30,058,791		29,791,719		26,815,550

Table of Contents

Comparison of the Three Months Ended September 30, 2024 and 2023

Results of Operations


	Three Months Ended September 30,
	2024		2023		$ Change		% Change

Revenue:
Platforms	$	4,329,645	$	2,600,192	$	1,729,453	66.5	%
Transactions		7,714,837		7,460,779		254,058	3.4	%
Total revenue		12,044,482		10,060,971		1,983,511	19.7	%

Cost of revenue:
Platforms		547,167		382,615		164,552	43.0	%
Transactions		5,731,439		5,646,791		84,648	1.5	%
Total cost of revenue		6,278,606		6,029,406		249,200	4.1	%

Gross profit:
Platforms		3,782,478		2,217,577		1,564,901	70.6	%
Transactions		1,983,398		1,813,988		169,410	9.3	%
Total gross profit		5,765,876		4,031,565		1,734,311	43.0	%

Operating expenses:
Sales and marketing		1,190,407		685,016		505,391	73.8	%
Technology and product development		1,372,758		1,244,579		128,179	10.3	%
General and administrative		1,930,176		2,542,868		(612,692)	(24.1)	%
Depreciation and amortization		312,095		59,620		252,475	423.5	%
Stock-based compensation expense		417,989		591,814		(173,825)	(29.4)	%
Foreign currency transaction loss (gain)		(104,240)		6,620		(110,860)	(1,674.6)	%
Total operating expenses		5,119,185		5,130,517		(11,332)	(0.2)	%

Income (loss) from operations		646,691		(1,098,952)		1,745,643	158.8	%

Other income		68,525		140,311		(71,786)	(51.2)	%

Income (loss) from operations before provision for income taxes		715,216		(958,641)		1,673,857	174.6	%
Provision for income taxes		(46,212)		(29,402)		(16,810)	(57.2)	%

Net income (loss)	$	669,004	$	(988,043)		1,657,047	167.7	%

Table of Contents

Revenue


	Three Months Ended September 30,
	2024		2023		$ Change		% Change
Revenue:
Platforms	$	4,329,645	$	2,600,192	$	1,729,453	66.5	%
Transactions		7,714,837		7,460,779		254,058	3.4	%
Total revenue	$	12,044,482	$	10,060,971	$	1,983,511	19.7	%

Total revenue increased $1,983,511, or 19.7%, for the three months ended September 30, 2024 compared to the prior year, due to the following:


Category	Impact			Key Drivers
Platforms	↑	$	1,729,453	Increased due to additional deployments to new and existing customers, expansion from existing customers and additional revenue from the Scite acquisition. Revenue is recognized ratably over the term of the subscription agreement, which is typically one year for commercial customers and monthly for individual subscribers, provided all other revenue recognition criteria have been met. Billings or payments received in advance of revenue recognition are recorded as deferred revenue.
Transactions	↑	$	254,058	Increased primarily due to organic higher copyright revenues.

Cost of Revenue


	Three Months Ended September 30,
	2024		2023		$ Change		% Change
Cost of Revenue:
Platforms	$	547,167	$	382,615	$	164,552	43.0	%
Transactions		5,731,439		5,646,791		84,648	1.5	%
Total cost of revenue	$	6,278,606	$	6,029,406	$	249,200	4.1	%


	Three Months Ended
	September 30,
	2024		2023		% Change *
As a percentage of revenue:
Platforms	12.6	%	14.7	%	(2.1)	%
Transactions	74.3	%	75.7	%	(1.4)	%
Total	52.1	%	59.9	%	(7.8)	%

*	The difference between current and prior period cost of revenue as a percentage of revenue

Total cost of revenue as a percentage of revenue decreased 7.8%, from 59.9% for the previous year to 52.1%, for the three months ended September 30, 2024.


	Impact as percentage
Category	of revenue			Key Drivers
Platforms	↓	2.1	%	Decreased primarily due to lower personnel costs.
Transactions	↓	1.4	%	Decreased primarily due to higher copyright margins slightly offset by lower service fee margins.

Table of Contents

Gross Profit


	Three Months Ended September 30,
	2024		2023		$ Change		% Change
Gross Profit:
Platforms	$	3,782,478	$	2,217,577	$	1,564,901	70.6	%
Transactions		1,983,398		1,813,988		169,410	9.3	%
Total gross profit	$	5,765,876	$	4,031,565	$	1,734,311	43.0	%


	Three Months Ended
	September 30,
	2024		2023		% Change*
As a percentage of revenue:
Platforms	87.4	%	85.3	%	2.1	%
Transactions	25.7	%	24.3	%	1.4	%
Total	47.9	%	40.1	%	7.8	%

*	The difference between current and prior period gross profit as a percentage of revenue

Operating Expenses


	Three Months Ended September 30,
	2024		2023		$ Change		% Change
Operating Expenses:
Sales and marketing	$	1,190,407	$	685,016	$	505,391	73.8	%
Technology and product development		1,372,758		1,244,579		128,179	10.3	%
General and administrative		1,930,176		2,542,868		(612,692)	(24.1)	%
Depreciation and amortization		312,095		59,620		252,475	423.5	%
Stock-based compensation expense		417,989		591,814		(173,825)	(29.4)	%
Foreign currency transaction loss (gain)		(104,240)		6,620		(110,860)	(1,674.6)	%
Total operating expenses	$	5,119,185	$	5,130,517	$	(11,332)	(0.2)	%


Category	Impact			Key Drivers
Sales and marketing	↑	$	505,391	Increased primarily due to greater personnel costs, consulting expenses and marketing discretionary spend, most of which is related to the additional cost base associated with the Scite acquisition.
Technology and product development	↑	$	128,179	Increased due to greater software development personnel costs, most of which is related to the additional cost base associated with the Scite acquisition.
General and administrative	↓	$	612,692	Decreased due to lower legal expenses and personnel costs, partially offset by greater recruiting expenses.

Net Income (Loss)


	Three Months Ended September 30,
	2024		2023		$ Change		% Change
Net Income (Loss):
Net income (loss):	$	669,004	$	(988,043)	$	1,657,047	167.7	%

Net income increased $1,657,047, or 167.7%, for the three months ended September 30, 2024 compared to the prior year, primarily due to increased gross profit and decreased operating expenses as described above.

Table of Contents

Liquidity and Capital Resources


	Three Months Ended September 30,
	2024		2023
Consolidated Statements of Cash Flow Data:
Net cash provided by (used in) operating activities	$	843,119	$	(755,571)
Net cash used in investing activities		—		(2,752,078)
Net cash used in financing activities		(16,119)		(156,325)

Effect of exchange rate changes		(2,258)		705
Net increase (decrease) in cash and cash equivalents		824,742		(3,663,269)
Cash and cash equivalents, beginning of period		6,100,031		13,545,333
Cash and cash equivalents, end of period	$	6,924,773	$	9,882,064

Liquidity

As of September 30, 2024, we had cash and cash equivalents of $6,924,773, compared to $6,100,031 as of June 30, 2024, an increase of $824,742. This increase was primarily due to cash provided by operating activities.

Operating Activities

Net cash provided by operating activities was $843,119 for the three months ended September 30, 2024 and resulted primarily from a decrease in accounts receivable of $566,194 and a decrease in prepaid royalties of $494,713, partially offset by a decrease in deferred revenue of $992,792.

Net cash used in operating activities was $755,571 for the three months ended September 30, 2023 and resulted primarily from a decrease in deferred revenue of $646,830 and an increase in accounts receivable of $112,965.

Investing Activities

Net cash used in investing activities was $0 for the three months ended September 30, 2024.

Net cash used in investing activities was $2,752,078 for the three months ended September 30, 2023 and resulted primarily from the payment for the ResoluteAI acquisition of $2,718,253.

Financing Activities

Net cash used in financing activities was $16,119 for the three months ended September 30, 2024 and resulted from repurchase of common stock of $16,119.

Net cash used in financing activities was $156,325 for the three months ended September 30, 2023 and resulted from the payment of contingent acquisition consideration of $110,190 and the repurchase of common stock of $46,135.

On April 15, 2024, we entered into a Loan Agreement (the “PNC Loan Agreement”) with PNC Bank, National Association (“PNC”), as lender. Pursuant to the PNC Loan Agreement, we entered into a Revolving Line of Credit Note (the “PNC Note”) with PNC, which provides for a $500,000 secured revolving line of credit that matures on April 15, 2025 and bears interest annually at the daily SOFR rate plus 2.5%, with accrued interest due and payable monthly. The PNC Note contains customary events of default including, among other things, payment defaults, material misrepresentations, breaches of covenants, revocation of guarantee, certain bankruptcy and insolvency events. There were no outstanding borrowings under the line of credit as of September 30, 2024.

Table of Contents

Non-GAAP Measure – Adjusted EBITDA

In addition to our GAAP results, we present Adjusted EBITDA as a supplemental measure of our performance. However, Adjusted EBITDA is not a recognized measurement under GAAP and should not be considered as an alternative to net income, income from operations or any other performance measure derived in accordance with GAAP or as an alternative to cash flow from operating activities as a measure of liquidity. We define Adjusted EBITDA as net income (loss), plus interest expense, other income (expense) including any change in fair value of contingent earnout liability, foreign currency transaction loss, provision for income taxes, depreciation and amortization, stock-based compensation, income from discontinued operations and gain on sale of discontinued operations. Management considers our core operating performance to be that which our managers can affect in any particular period through their management of the resources that affect our underlying revenue and profit generating operations that period. Non-GAAP adjustments to our results prepared in accordance with GAAP are itemized below. You are encouraged to evaluate these adjustments and the reasons we consider them appropriate for supplemental analysis. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.

Set forth below is a reconciliation of Adjusted EBITDA to net income (loss) for the three months ended September 30, 2024 and 2023:


	Three Months Ended
	September 30,
	2024		2023		$ Change			% Change
Net income (loss)	$	669,004	$	(988,043)	$	1,657,047	$	167.7	%
Add (deduct):
Other (income) expense		(68,525)		(140,311)		71,786		51.2	%
Foreign currency transaction loss (gain)		(104,240)		6,620		(110,860)		(1,674.6)	%
Provision for income taxes		46,212		29,402		16,810		57.2	%
Depreciation and amortization		312,095		59,620		252,475		423.5	%
Stock-based compensation		417,989		591,814		(173,825)		(29.4)	%
Adjusted EBITDA	$	1,272,535	$	(440,898)	$	1,713,433	$	388.6	%

We present Adjusted EBITDA because we believe it assists investors and analysts in comparing our performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. In addition, we use Adjusted EBITDA in developing our internal budgets, forecasts and strategic plan; in analyzing the effectiveness of our business strategies in evaluating potential acquisitions; and in making compensation decisions and in communications with our board of directors concerning our financial performance. Adjusted EBITDA has limitations as an analytical tool, which includes, among others, the following:

●

Adjusted EBITDA does not reflect our cash expenditures, or future requirements, for capital expenditures or contractual commitments;

●

Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

●

Adjusted EBITDA does not reflect interest expense, or the cash requirements necessary to service interest or principal payments, on our debts; and

●

Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for such replacements.

Table of Contents

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. For purposes of this section, the term disclosure controls and procedures means controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2024, the end of the period covered by this report, our disclosure controls and procedures were effective at a reasonable assurance level.

Inherent Limitations on the Effectiveness of Controls

Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in a cost-effective control system, no evaluation of internal control over financial reporting can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been or will be detected.

These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of a simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Projections of any evaluation of controls effectiveness to future periods are subject to risks. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures.

Changes in Internal Control Over Financial Reporting

In addition, our management with the participation of our principal executive officer and principal financial officer have determined that no change in our internal control over financial reporting (as that term is defined in Rules 13(a)-15(f) and 15(d)-15(f) of the Exchange Act) occurred during the quarter ended September 30, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II — OTHER INFORMATION

Item 1A. Risk Factors.

There have been no material changes from the risk factors disclosed in the Company's Annual Report on Form 10-K for the year ended June 30, 2024.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the three months ended September 30, 2024, we repurchased 5,757 shares of our common stock from employees at an average market price of approximately $2.80 per share for an aggregate amount of $16,119. As of September 30, 2024, $330,774 remains under the current authorization to repurchase our outstanding common stock from our employees.

The following table summarizes repurchases of our common stock on a monthly basis:


				Total Number of Shares	Approximate Dollar Value
	Total Number	Average		Purchased as Part of	of Shares that May Yet Be
	of Shares	Price Paid		Publicly Announced	Purchased Under the
Period	Purchased¹	per Share		Plans or Programs	Plans or Programs
July 1-31, 2024	—		—	—	$	346,893
August 1-31, 2024	—		—	—	$	346,893
September 1-30, 2024	5,757	$	2.80	—	$	330,774
Total	5,757	$	2.80	—		—

¹ Consists of shares of common stock purchased from an employee to satisfy tax obligations in connection with the vesting of stock incentive awards.

Table of Contents

Item 6. Exhibits

EXHIBIT INDEX


		Incorporated by Reference
Exhibit Number	Exhibit Description	Form	Date	Number	Filed Herewith
2.1	Share Exchange Agreement between Research Solutions, Inc. and Reprints Desk Inc. dated as of November 13, 2006.	SB-2	12/28/2007	2.1
2.2	Agreement and Plan of Merger by and among Reprints Desk, Inc., Research Solutions Acquisition Corp 1, Research Solutions, Inc., as Parent Guarantor, Resolute Innovation, Inc. and Shareholder Representative Services LLC dated as of July 28, 2023.	8-K	7/31/2023	2.1
2.3	Agreement of Merger and Plan of Reorganization, by and among the Research Solutions, Inc., Research Solutions Acquisition 2, LLC, Scite, Inc., and the Stockholder Representative, dated as of November 24, 2023.	8-K	11/24/2023	2.1
3.1.1	Articles of Incorporation.	SB-2	12/28/2007	3.1
3.1.2	Articles of Merger Effective March 4, 2013.	8-K	3/6/2013	3.1
3.2	Amended and Restated Bylaws.	8-K	10/17/2012	3.2
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer
32.1	Section 1350 Certification of Chief Executive Officer				*
32.2	Section 1350 Certification of Chief Financial Officer				*
101.INS	INLINE XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	XBRL Taxonomy Extension Definition Linkbase
101.LAB	XBRL Taxonomy Extension Label Linkbase
101.PRE	XBRL Taxonomy Extension Presentation Linkbase
104	Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)

* Furnished herewith

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	RESEARCH SOLUTIONS, INC.

	By:	/s/ Roy W. Olivier
		Roy W. Olivier
Date: November 14, 2024		Chief Executive Officer and President (Principal Executive Officer)

	By:	/s/ William Nurthen
		William Nurthen
Date: November 14, 2024		Chief Financial Officer (Principal Financial and Accounting Officer)

Exhibit 31.1

RULE 13a-14(a) CERTIFICATION

I, Roy W. Olivier, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Research Solutions, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 14, 2024		/s/ Roy W. Olivier
		Roy W. Olivier
		Chief Executive Officer and President (Principal Executive Officer)

Exhibit 31.2

RULE 13a-14(a) CERTIFICATION

I, William Nurthen, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Research Solutions, Inc.;

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 14, 2024		/s/ William Nurthen
		William Nurthen
		Chief Financial Officer (Principal Financial and
		Accounting Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Research Solutions, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Roy W. Olivier, Chief Executive Officer and President, and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Roy W. Olivier
Roy W. Olivier
Chief Executive Officer and President (Principal Executive Officer)
November 14, 2024

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the quarterly report of Research Solutions, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, William Nurthen, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ William Nurthen
William Nurthen
Chief Financial Officer (Principal Financial and Accounting Officer)
November 14, 2024

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Sep. 30, 2024	Nov. 08, 2024
Document And Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2024
Document Transition Report	false
Securities Act File Number	001-39256
Entity Registrant Name	RESEARCH SOLUTIONS, INC.
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	11-3797644
Entity Address, Address Line One	Address not applicable
Entity Address, City or Town	N/A
Entity Address, Postal Zip Code	N/A
Entity Address, State or Province	NV
City Area Code	310
Local Phone Number	477-0354
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	RSSS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,513,172
Entity Central Index Key	0001386301
Current Fiscal Year End Date	--06-30
Document Fiscal Year Focus	2025
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Current assets:
Cash and cash equivalents	$ 6,924,773	$ 6,100,031
Accounts receivable, net of allowance of $101,949 and $68,579, respectively	6,298,606	6,879,800
Prepaid expenses and other current assets	649,497	643,553
Prepaid royalties	572,524	1,067,237
Total current assets	14,445,400	14,690,621
Non-current assets:
Property and equipment, net of accumulated depreciation of $927,386 and $922,558, respectively	71,659	88,011
Intangible assets, net of accumulated amortization of $1,834,897 and $1,535,310, respectively ($8,117,222 provisional)	10,497,023	10,764,261
Goodwill ($13,171,486 provisional)	16,345,888	16,315,888
Deposits and other assets	915	981
Total assets	41,360,885	41,859,762
Current liabilities:
Accounts payable and accrued expenses	8,257,821	8,843,612
Deferred revenue	8,046,056	9,023,848
Total current liabilities	16,303,877	17,867,460
Non-current liabilities:
Contingent earnout liability	12,298,114	12,298,114
Total liabilities	28,601,991	30,165,574
Commitments and contingencies
Stockholders' equity:
Preferred stock; $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock; $0.001 par value; 100,000,000 shares authorized; 32,513,172 and 32,295,373 shares issued and outstanding, respectively	32,513	32,295
Additional paid-in capital	38,491,610	38,089,958
Accumulated deficit	(25,640,242)	(26,309,246)
Accumulated other comprehensive loss	(124,987)	(118,819)
Total stockholders' equity	12,758,894	11,694,188
Total liabilities and stockholders' equity	$ 41,360,885	$ 41,859,762

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2024	Jun. 30, 2024
Net of allowance	$ 101,949	$ 68,579
Property and equipment, net of accumulated depreciation	927,386	922,558
Intangible assets, net of accumulated amortization	1,834,897	1,535,310
Goodwill	16,345,888	$ 16,315,888
Intangible assets, provisional	$ 8,117,222
Preferred stock, par or stated value per share	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par or stated value per share	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares, issued	32,513,172	32,295,373
Common stock, shares, outstanding	32,513,172	32,295,373
Scite
Goodwill	$ 13,171,486	$ 13,171,486

Condensed Consolidated Statements of Operations and Other Comprehensive Income (Loss) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Total revenue	$ 12,044,482	$ 10,060,971
Cost of revenue:
Total cost of revenue	6,278,606	6,029,406
Gross profit	5,765,876	4,031,565
Operating expenses:
Selling, general and administrative	4,807,090	5,070,897
Depreciation and amortization	312,095	59,620
Total operating expenses	5,119,185	5,130,517
Income (loss) from operations	646,691	(1,098,952)
Other income	68,525	140,311
Income (loss) from operations before provision for income taxes	715,216	(958,641)
Provision for income taxes	(46,212)	(29,402)
Net income (loss)	669,004	(988,043)
Other comprehensive income (loss):
Foreign currency translation	(6,168)	(946)
Comprehensive income (loss)	$ 662,836	$ (988,989)
Basic income (loss) per common share:
Net income (loss) per share (in dollars per share)	$ 0.02	$ (0.04)
Weighted average common shares outstanding	30,346,871	27,052,445
Diluted income (loss) per common share:
Net income (loss) per share (in dollars per share)	$ 0.02	$ (0.04)
Weighted average common shares outstanding	33,234,858	27,052,445
Platforms
Revenue:
Total revenue	$ 4,329,645	$ 2,600,192
Cost of revenue:
Total cost of revenue	547,167	382,615
Transactions
Revenue:
Total revenue	7,714,837	7,460,779
Cost of revenue:
Total cost of revenue	$ 5,731,439	$ 5,646,791

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Other Comprehensive Loss	Total
Balance at Jun. 30, 2023	$ 29,487	$ 29,941,873	$ (22,522,649)	$ (118,224)	$ 7,330,487
Balance (in shares) at Jun. 30, 2023	29,487,508
Fair value of vested stock options		17,471			17,471
Fair value of vested restricted common stock	$ 105	574,238			574,343
Fair value of vested restricted common stock (in shares)	105,000
Repurchase of common stock	$ (19)	(46,116)			(46,135)
Repurchase of common stock (in shares)	(18,603)
Common stock issued upon exercise of stock options	$ 51	(51)
Common stock issued upon exercise of stock options (in shares)	50,180
Net income (loss) for the period			(988,043)		(988,043)
Foreign currency translation				(946)	(946)
Balance at Sep. 30, 2023	$ 29,624	30,487,415	(23,510,692)	(119,170)	6,887,177
Balance (in shares) at Sep. 30, 2023	29,624,085
Balance at Jun. 30, 2023	$ 29,487	29,941,873	(22,522,649)	(118,224)	7,330,487
Balance (in shares) at Jun. 30, 2023	29,487,508
Balance at Jun. 30, 2024	$ 32,295	38,089,958	(26,309,246)	(118,819)	11,694,188
Balance (in shares) at Jun. 30, 2024	32,295,373
Fair value of vested stock options		28,856			28,856
Fair value of vested restricted common stock	$ 250	388,883			389,133
Fair value of vested restricted common stock (in shares)	250,000
Forfeited restricted common stock	$ (48)	48
Forfeited restricted common stock (in shares)	(48,584)
Repurchase of common stock	$ (6)	(16,113)			$ (16,119)
Repurchase of common stock (in shares)	(5,757)
Common stock issued upon exercise of stock options	$ 22	(22)
Common stock issued upon exercise of stock options (in shares)	22,140				74,321
Net income (loss) for the period			669,004		$ 669,004
Foreign currency translation				(6,168)	(6,168)
Balance at Sep. 30, 2024	$ 32,513	$ 38,491,610	$ (25,640,242)	$ (124,987)	$ 12,758,894
Balance (in shares) at Sep. 30, 2024	32,513,172

Condensed Consolidated Statements of Cash Flows	3 Months Ended
Condensed Consolidated Statements of Cash Flows	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)
Cash flow from operating activities:
Net income (loss)	$ 669,004	$ (988,043)
Adjustment to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	312,095	59,620
Fair value of vested stock options	28,856	17,471
Fair value of vested restricted common stock	389,133	574,343
Changes in operating assets and liabilities:
Accounts receivable	566,194	(112,965)
Prepaid expenses and other current assets	(5,944)	109,946
Prepaid royalties	494,713	35,140
Accounts payable and accrued expenses	(618,140)	195,747
Deferred revenue	(992,792)	(646,830)
Net cash provided by (used in) operating activities	843,119	(755,571)
Cash flow from investing activities:
Purchase of property and equipment		(33,825)
Net cash used in investing activities		(2,752,078)
Cash flow from financing activities:
Common stock repurchase	(16,119)	(46,135)
Payment of contingent acquisition consideration		(110,190)
Net cash used in financing activities	(16,119)	(156,325)
Effect of exchange rate changes	(2,258)	705
Net increase (decrease) in cash and cash equivalents	824,742	(3,663,269)
Cash and cash equivalents, beginning of period	6,100,031	13,545,333
Cash and cash equivalents, end of period	6,924,773	9,882,064
Supplemental disclosures of cash flow information:
Cash paid for income taxes	46,212	29,402
Non-cash investing and financing activities:
Contingent consideration accrual on asset acquisition	$ 33,353	42,989
Resolute
Cash flow from investing activities:
Payment for acquisition, net of cash acquired		$ (2,718,253)

Organization, Nature of Business and Basis of Presentation

3 Months Ended

Sep. 30, 2024

Organization, Nature of Business and Basis of Presentation

Organization, Nature of Business and Basis of Presentation

Note 1. Organization, Nature of Business and Basis of Presentation

Organization

Nature of Business

Platforms

Transactions

Principles of Consolidation

Basis of Presentation

Summary of Significant Accounting Policies

3 Months Ended

Sep. 30, 2024

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

Note 2. Summary of Significant Accounting Policies

Use of Estimates

Concentration of Credit Risk

The Company has no customers that represent 10% of revenue or more for the three months ended September 30, 2024 and 2023.

The Company has no customers that accounted for greater than 10% of accounts receivable at September 30, 2024 and June 30, 2024.

The following table summarizes vendor concentrations:


	Three Months Ended
	September 30,
	2024		2023
Vendor A	26	%	24	%
Vendor B	10	%	11	%

Revenue Recognition

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

●

identify the contract with a customer;

●

identify the performance obligations in the contract;

●

determine the transaction price;

●

allocate the transaction price to performance obligations in the contract; and

●

recognize revenue as the performance obligation is satisfied.

Platforms

Transactions

Revenue by Geographical Region

The following table summarizes revenue by geographical region:


	Three Months Ended
	September 30,
	2024				2023
United States	$	7,118,728	59.1	%	$	5,861,032	58.3	%
Europe		3,847,411	31.9	%		3,155,709	31.3	%
Rest of World		1,078,343	9.0	%		1,044,230	10.4	%
Total	$	12,044,482	100	%	$	10,060,971	100	%

Accounts Receivable by Geographical Region

The following table summarizes accounts receivable by geographical region:


	As of September 30, 2024				As of June 30, 2024
United States	$	3,491,224	55.4	%	$	4,125,696	60.0	%
Europe		2,242,100	35.6	%		2,082,900	30.2	%
Rest of World		565,282	9.0	%		671,204	9.8	%
Total	$	6,298,606	100	%	$	6,879,800	100	%

Business Combinations

Intangible Assets

Goodwill

Deferred Revenue

Cost of Revenue

Platforms

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

Transactions

Stock-Based Compensation

Foreign Currency

The following table summarizes the exchange rates used:


	Three Months Ended		Year Ended
	September 30,		June 30,
	2024	2023	2024	2023
Period end Euro : US Dollar exchange rate	1.12	1.06	1.07	1.09
Average period Euro : US Dollar exchange rate	1.09	1.10	1.08	1.05

Period end GBP : US Dollar exchange rate	1.34	1.22	1.26	1.27
Average period GBP : US Dollar exchange rate	1.29	1.28	1.26	1.20

Period end Mexican Peso : US Dollar exchange rate	0.05	0.06	0.05	0.06
Average period Mexican Peso : US Dollar exchange rate	0.05	0.06	0.06	0.05

Net Income (Loss) Per Share

The following table reconciles the numerators and denominators used in the computations of both basic and diluted earnings per share:


	Three Months Ended
	September 30,
	2024		2023

Net income (loss) available to common shareholders	$	669,004	$	(988,043)

Weighted average commons shares - basic		30,346,871		27,052,445
Dilutive effect of outstanding warrants and stock options		810,481		—
Dilutive effect of unvested restricted common stock		2,077,506		—
Weighted average commons shares - diluted		33,234,858		27,052,445

Net income (loss) per common share:
Basic	$	0.02	$	(0.04)
Diluted	$	0.02	$	(0.04)

Fair Value of Financial Instruments

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

Level 3 – Unobservable inputs based on the Company’s assumptions.

The Company is required to use observable market data if such data is available without undue cost and effort.

Recently Issued Accounting Pronouncements

Line of Credit

3 Months Ended

Sep. 30, 2024

Line of Credit

Line of Credit

Note 3. Line of Credit

Stockholders' Equity

3 Months Ended

Sep. 30, 2024

Stockholders' Equity

Stockholders' Equity

Note 4. Stockholders’ Equity

Stock Options

The following table summarizes vested and unvested stock option activity:


	All Options			Vested Options			Unvested Options
		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at June 30, 2024	2,788,625	$	1.93	2,529,856	$	1.85	258,769	$	2.73
Granted	—		—	—		—	—		—
Options vesting	—		—	417		2.19	(417)		2.19
Exercised	(74,321)		1.92	(74,321)		1.92	—		—
Forfeited	—		—	—		—	—		—
Outstanding at September 30, 2024	2,714,304	$	1.93	2,455,952	$	1.84	258,352	$	2.73

The following table presents the information regarding stock options outstanding and exercisable as of September 30, 2024:


	Option		Remaining
	Exercise	Options	Contractual	Options
	Price	Outstanding	Life (in years)	Exercisable
$	0.70	225,000	1.18	225,000
	0.80	16,000	0.89	16,000
	0.90	15,000	0.84	15,000
	1.00	15,000	0.44	15,000
	1.05	305,000	1.90	305,000
	1.09	40,000	1.65	40,000
	1.10	105,000	0.75	105,000
	1.20	247,000	3.14	247,000
	1.59	25,000	3.61	25,000
	2.10	238,767	7.36	238,767
	2.13	211,500	6.13	211,500
	2.15	200,000	8.19	200,000
	2.17	28,000	6.61	28,000
	2.19	5,000	7.30	4,582
	2.40	284,000	4.12	284,000
	2.43	61,250	6.68	61,250
	2.45	89,500	5.84	89,500
	2.49	73,000	5.61	73,000
	2.50	20,000	4.63	20,000
	2.64	7,353	6.85	7,353
	2.67	21,000	6.96	21,000
	2.73	257,934	9.19	—
	2.99	8,000	5.62	8,000
	3.13	208,000	5.12	208,000
	3.50	8,000	5.37	8,000
	Total	2,714,304		2,455,952

Restricted Common Stock

•20% at a 30-day VWAP of $3.00 per share (this vesting occurred on March 14, 2024);

•20% at a 30-day VWAP of $3.75 per share;

•20% at a 30-day VWAP of $4.50 per share;

•20% at a 30-day VWAP of $5.25 per share; and

•20% at a 30-day VWAP of $6.00 per share.

The following table summarizes restricted common stock activity:


				Weighted
				Average
	Number of			Grant Date
	Shares	Fair Value		Fair Value
Non-vested, June 30, 2024	1,957,726	$	1,375,199	$	1.63
Granted	250,000		532,000		2.13
Vested	(29,619)		(389,133)		2.14
Forfeited	(48,584)		(96,925)		2.18
Non-vested, September 30, 2024	2,129,523	$	1,421,141	$	1.67

Common Stock Repurchases

Acquisitions

3 Months Ended

Sep. 30, 2024

Acquisitions

Acquisitions

Note 5. Acquisitions

FIZ

ResoluteAI

Scite


	Pro Forma (Unaudited)
	Three Months ended September 30,
	2024		2023

Revenue	$	12,044,482	$	10,800,908
Cost of revenue		6,278,606		6,090,058
Gross profit		5,765,876		4,710,850

Total operating expenses		5,119,185		5,673,375

Loss from operations		646,691		(962,525)

Other income (expense)		68,525		141,313

Income (loss) from operations before provision for income taxes		715,216		(821,212)
Provision for income taxes		(46,212)		(29,402)

Pro Forma Net income (loss)	$	669,004	$	(850,614)
Pro Forma Net income (loss) per weighted average share, basic	$	0.02	$	(0.03)
Pro Forma Net income (loss) per weighted average share, diluted	$	0.02	$	(0.03)


In thousands	ResoluteAI		Scite
Fair value of consideration
Cash	$	2,774	$	7,217
Holdback cash paid		125		175
Common Stock (2,729,014 shares at $2.40 per share)		—		6,549
Contingent earn-out		1,867		7,194
Total purchase price		4,766		21,135

Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Cash and cash equivalents		59		—
Accounts receivable		162		109
Prepaid expenses		43		—
Accounts payable and accrued expenses		(33)		—
Deferred revenue		(649)		(997)
Other current liabilities		(60)		(18)
Net tangible assets		(478)		(906)

Intangible assets:
Developed technology		2,000		8,800
Customer relationships		100		70
Net identifiable intangible assets		2,100		8,870

Goodwill		3,144		13,171

Fair value of net assets acquired	$	4,766	$	21,135

Contingencies

3 Months Ended

Sep. 30, 2024

Contingencies

Contingencies

Note 6. Contingencies

Inflation Risk

Subsequent Events

3 Months Ended

Sep. 30, 2024

Subsequent Events

Subsequent Events

Note 7. Subsequent Events

On November 12, 2024, the Company granted 340,000 shares of restricted common stock to an employee under the long-term equity bonus plan, or LTEBP.

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Sep. 30, 2024

Summary of Significant Accounting Policies

Use of Estimates

Concentration of Credit Risk

The Company has no customers that represent 10% of revenue or more for the three months ended September 30, 2024 and 2023.

The Company has no customers that accounted for greater than 10% of accounts receivable at September 30, 2024 and June 30, 2024.

The following table summarizes vendor concentrations:


	Three Months Ended
	September 30,
	2024		2023
Vendor A	26	%	24	%
Vendor B	10	%	11	%

Revenue Recognition

The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

●

identify the contract with a customer;

●

identify the performance obligations in the contract;

●

determine the transaction price;

●

allocate the transaction price to performance obligations in the contract; and

●

recognize revenue as the performance obligation is satisfied.

Platforms

Transactions

Revenue by Geographical Region

The following table summarizes revenue by geographical region:


	Three Months Ended
	September 30,
	2024				2023
United States	$	7,118,728	59.1	%	$	5,861,032	58.3	%
Europe		3,847,411	31.9	%		3,155,709	31.3	%
Rest of World		1,078,343	9.0	%		1,044,230	10.4	%
Total	$	12,044,482	100	%	$	10,060,971	100	%

Accounts Receivable by Geographical Region

The following table summarizes accounts receivable by geographical region:


	As of September 30, 2024				As of June 30, 2024
United States	$	3,491,224	55.4	%	$	4,125,696	60.0	%
Europe		2,242,100	35.6	%		2,082,900	30.2	%
Rest of World		565,282	9.0	%		671,204	9.8	%
Total	$	6,298,606	100	%	$	6,879,800	100	%

Business Combinations

Platforms

Cost of Platform revenue consists primarily of personnel costs of our operations team, and to a lesser extent managed hosting providers and other third-party service and data providers.

Transactions

Stock-Based Compensation

Foreign Currency

The following table summarizes the exchange rates used:


	Three Months Ended		Year Ended
	September 30,		June 30,
	2024	2023	2024	2023
Period end Euro : US Dollar exchange rate	1.12	1.06	1.07	1.09
Average period Euro : US Dollar exchange rate	1.09	1.10	1.08	1.05

Period end GBP : US Dollar exchange rate	1.34	1.22	1.26	1.27
Average period GBP : US Dollar exchange rate	1.29	1.28	1.26	1.20

Period end Mexican Peso : US Dollar exchange rate	0.05	0.06	0.05	0.06
Average period Mexican Peso : US Dollar exchange rate	0.05	0.06	0.06	0.05

Net Income (Loss) Per Share

The following table reconciles the numerators and denominators used in the computations of both basic and diluted earnings per share:


	Three Months Ended
	September 30,
	2024		2023

Net income (loss) available to common shareholders	$	669,004	$	(988,043)

Weighted average commons shares - basic		30,346,871		27,052,445
Dilutive effect of outstanding warrants and stock options		810,481		—
Dilutive effect of unvested restricted common stock		2,077,506		—
Weighted average commons shares - diluted		33,234,858		27,052,445

Net income (loss) per common share:
Basic	$	0.02	$	(0.04)
Diluted	$	0.02	$	(0.04)

Fair Value of Financial Instruments

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

Level 3 – Unobservable inputs based on the Company’s assumptions.

The Company is required to use observable market data if such data is available without undue cost and effort.

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Sep. 30, 2024

Summary of Significant Accounting Policies

Schedule of vendor concentration risk percentage


	Three Months Ended
	September 30,
	2024		2023
Vendor A	26	%	24	%
Vendor B	10	%	11	%

Schedule of revenue by geographical region


	Three Months Ended
	September 30,
	2024				2023
United States	$	7,118,728	59.1	%	$	5,861,032	58.3	%
Europe		3,847,411	31.9	%		3,155,709	31.3	%
Rest of World		1,078,343	9.0	%		1,044,230	10.4	%
Total	$	12,044,482	100	%	$	10,060,971	100	%

Schedule of accounts receivable by geographical region


	As of September 30, 2024				As of June 30, 2024
United States	$	3,491,224	55.4	%	$	4,125,696	60.0	%
Europe		2,242,100	35.6	%		2,082,900	30.2	%
Rest of World		565,282	9.0	%		671,204	9.8	%
Total	$	6,298,606	100	%	$	6,879,800	100	%

Schedule of foreign currency exchange rate


	Three Months Ended		Year Ended
	September 30,		June 30,
	2024	2023	2024	2023
Period end Euro : US Dollar exchange rate	1.12	1.06	1.07	1.09
Average period Euro : US Dollar exchange rate	1.09	1.10	1.08	1.05

Period end GBP : US Dollar exchange rate	1.34	1.22	1.26	1.27
Average period GBP : US Dollar exchange rate	1.29	1.28	1.26	1.20

Period end Mexican Peso : US Dollar exchange rate	0.05	0.06	0.05	0.06
Average period Mexican Peso : US Dollar exchange rate	0.05	0.06	0.06	0.05

Schedule of earnings per share, basic and diluted


	Three Months Ended
	September 30,
	2024		2023

Net income (loss) available to common shareholders	$	669,004	$	(988,043)

Weighted average commons shares - basic		30,346,871		27,052,445
Dilutive effect of outstanding warrants and stock options		810,481		—
Dilutive effect of unvested restricted common stock		2,077,506		—
Weighted average commons shares - diluted		33,234,858		27,052,445

Net income (loss) per common share:
Basic	$	0.02	$	(0.04)
Diluted	$	0.02	$	(0.04)

Stockholders' Equity (Tables)

3 Months Ended

Sep. 30, 2024

Stockholders' Equity

Schedule of vested and unvested stock option activity


	All Options			Vested Options			Unvested Options
		Weighted			Weighted			Weighted
		Average			Average			Average
		Exercise			Exercise			Exercise
	Shares	Price		Shares	Price		Shares	Price
Outstanding at June 30, 2024	2,788,625	$	1.93	2,529,856	$	1.85	258,769	$	2.73
Granted	—		—	—		—	—		—
Options vesting	—		—	417		2.19	(417)		2.19
Exercised	(74,321)		1.92	(74,321)		1.92	—		—
Forfeited	—		—	—		—	—		—
Outstanding at September 30, 2024	2,714,304	$	1.93	2,455,952	$	1.84	258,352	$	2.73

Schedule of additional information regarding stock options outstanding and exercisable


	Option		Remaining
	Exercise	Options	Contractual	Options
	Price	Outstanding	Life (in years)	Exercisable
$	0.70	225,000	1.18	225,000
	0.80	16,000	0.89	16,000
	0.90	15,000	0.84	15,000
	1.00	15,000	0.44	15,000
	1.05	305,000	1.90	305,000
	1.09	40,000	1.65	40,000
	1.10	105,000	0.75	105,000
	1.20	247,000	3.14	247,000
	1.59	25,000	3.61	25,000
	2.10	238,767	7.36	238,767
	2.13	211,500	6.13	211,500
	2.15	200,000	8.19	200,000
	2.17	28,000	6.61	28,000
	2.19	5,000	7.30	4,582
	2.40	284,000	4.12	284,000
	2.43	61,250	6.68	61,250
	2.45	89,500	5.84	89,500
	2.49	73,000	5.61	73,000
	2.50	20,000	4.63	20,000
	2.64	7,353	6.85	7,353
	2.67	21,000	6.96	21,000
	2.73	257,934	9.19	—
	2.99	8,000	5.62	8,000
	3.13	208,000	5.12	208,000
	3.50	8,000	5.37	8,000
	Total	2,714,304		2,455,952

Schedule of restricted common stock activity


				Weighted
				Average
	Number of			Grant Date
	Shares	Fair Value		Fair Value
Non-vested, June 30, 2024	1,957,726	$	1,375,199	$	1.63
Granted	250,000		532,000		2.13
Vested	(29,619)		(389,133)		2.14
Forfeited	(48,584)		(96,925)		2.18
Non-vested, September 30, 2024	2,129,523	$	1,421,141	$	1.67

Acquisitions (Tables)

3 Months Ended

Sep. 30, 2024

Acquisitions

Schedule of fair value of tangible assets, identifiable intangible assets, and assumed liabilities


In thousands	ResoluteAI		Scite
Fair value of consideration
Cash	$	2,774	$	7,217
Holdback cash paid		125		175
Common Stock (2,729,014 shares at $2.40 per share)		—		6,549
Contingent earn-out		1,867		7,194
Total purchase price		4,766		21,135

Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Cash and cash equivalents		59		—
Accounts receivable		162		109
Prepaid expenses		43		—
Accounts payable and accrued expenses		(33)		—
Deferred revenue		(649)		(997)
Other current liabilities		(60)		(18)
Net tangible assets		(478)		(906)

Intangible assets:
Developed technology		2,000		8,800
Customer relationships		100		70
Net identifiable intangible assets		2,100		8,870

Goodwill		3,144		13,171

Fair value of net assets acquired	$	4,766	$	21,135

Schedule of pro forma operating results


	Pro Forma (Unaudited)
	Three Months ended September 30,
	2024		2023

Revenue	$	12,044,482	$	10,800,908
Cost of revenue		6,278,606		6,090,058
Gross profit		5,765,876		4,710,850

Total operating expenses		5,119,185		5,673,375

Loss from operations		646,691		(962,525)

Other income (expense)		68,525		141,313

Income (loss) from operations before provision for income taxes		715,216		(821,212)
Provision for income taxes		(46,212)		(29,402)

Pro Forma Net income (loss)	$	669,004	$	(850,614)
Pro Forma Net income (loss) per weighted average share, basic	$	0.02	$	(0.03)
Pro Forma Net income (loss) per weighted average share, diluted	$	0.02	$	(0.03)

Organization, Nature of Business and Basis of Presentation (Details) item in Millions	3 Months Ended
	Sep. 30, 2024 subsidiary item
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of subsidiaries \| subsidiary	5
Number of existing STM articles on the platform	200
Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of newly published STM articles each year	2
Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of newly published STM articles each year	4

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended
	Sep. 30, 2024 USD ($) item	Sep. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)
FDIC insured amount	$ 250,000
Cash and cash equivalents	$ 6,924,773		$ 6,100,031
Number of revenue streams \| item	2
Estimated average useful life	10 years
Foreign currency transaction gain (loss)	$ 104,240	$ (6,620)
Maximum \| Scite \| Developed Technology and Customer Relationships
Estimated average useful life	10 years
Minimum \| Scite \| Developed Technology and Customer Relationships
Estimated average useful life	3 years
Europe financial institutions
Cash and cash equivalents	$ 418,135		$ 294,145

Summary of Significant Accounting Policies - Concentrations (Details) - Cost of Goods and Service Benchmark [Member] - Supplier Concentration Risk [Member]	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Vendor A
Concentration percentage	26.00%	24.00%
Vendor B
Concentration percentage	10.00%	11.00%

Summary of Significant Accounting Policies - Revenue (Details) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Revenues	$ 12,044,482	$ 10,060,971
Percentage of revenue	100.00%	100.00%
Accounts Receivable [Member]
Revenues	$ 6,298,606		$ 6,879,800
Percentage of revenue	100.00%		100.00%
UNITED STATES
Revenues	$ 7,118,728	$ 5,861,032
Percentage of revenue	59.10%	58.30%
UNITED STATES \| Accounts Receivable [Member]
Revenues	$ 3,491,224		$ 4,125,696
Percentage of revenue	55.40%		60.00%
Europe [Member]
Revenues	$ 3,847,411	$ 3,155,709
Percentage of revenue	31.90%	31.30%
Europe [Member] \| Accounts Receivable [Member]
Revenues	$ 2,242,100		$ 2,082,900
Percentage of revenue	35.60%		30.20%
Rest of World
Revenues	$ 1,078,343	$ 1,044,230
Percentage of revenue	9.00%	10.40%
Rest of World \| Accounts Receivable [Member]
Revenues	$ 565,282		$ 671,204
Percentage of revenue	9.00%		9.80%

Summary of Significant Accounting Policies - Exchange rates (Details)	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Euro to US Dollar
Period end exchange rate	1.12	1.06	1.07	1.09
Average period exchange rate	1.09	1.10	1.08	1.05
GBP To US Dollar
Period end exchange rate	1.34	1.22	1.26	1.27
Average period exchange rate	1.29	1.28	1.26	1.20
Mexican Peso to US Dollar
Period end exchange rate	0.05	0.06	0.05	0.06
Average period exchange rate	0.05	0.06	0.06	0.05

Summary of Significant Accounting Policies -Net Income (Loss) Per Share (Details) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Summary of Significant Accounting Policies
Net Income (Loss) Available to Common Stockholders, Basic	$ 669,004	$ (988,043)
Net Income (Loss) Available to Common Stockholders, Diluted	$ 669,004	$ (988,043)
Weighted average commons shares - basic	30,346,871	27,052,445
Dilutive effect of outstanding warrants and stock options	810,481
Dilutive effect of unvested restricted common stock	2,077,506
Weighted average commons shares - diluted	33,234,858	27,052,445
Net income (loss) per common share:
Basic (in dollars per share)	$ 0.02	$ (0.04)
Diluted (in dollars per share)	$ 0.02	$ (0.04)

Line of Credit (Details) - USD ($)	Apr. 15, 2024	Sep. 30, 2024
Outstanding borrowings under line of credit		$ 0
Revolving Credit Facility Member
Line of credit amount	$ 500,000
Line of credit facility maturity date	Apr. 15, 2025
Interest bearing rate	2.50%

Stockholders' Equity - Options Narrative (Details) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Nov. 17, 2021	Nov. 16, 2021	Nov. 17, 2020	Nov. 16, 2020	Nov. 21, 2017	Nov. 10, 2016	Nov. 09, 2016
Term number of years	5 years
Weighted average remaining contractual life of all options outstanding	4 years 10 months 2 days
Remaining contractual life for options vested and exercisable	4 years 4 months 17 days
Aggregate intrinsic value of options outstanding	$ 2,269,490
Aggregate intrinsic value of options vested and exercisable	2,269,265
Fair value of vested stock options	28,856	$ 17,471
Amount of unvested compensation related to stock options	$ 227,465
Common stock issued upon exercise of stock options	74,321
Common Stock [Member]
Common stock issued upon exercise of stock options	22,140	50,180
Employee Stock Option [Member]
Vesting period	3 years
Number of year(s) cliff vesting period	1 year
Term number of years	10 years
Employee Stock Option [Member] \| 2007 Plan
Number of shares authorized under the plan								7,000,000	5,000,000
Number of shares available for grant	0
Employee Stock Option [Member] \| 2017 Plan
Number of shares authorized under the plan							1,874,513
Number of shares available for grant	836,577
Employee Stock Option [Member] \| Omnibus Incentive 2017 Plan [Member]
Number of shares authorized under the plan			6,874,513	3,374,513	3,374,513	2,374,513

Stockholders' Equity - Stock option Activity (Details)	3 Months Ended
Stockholders' Equity - Stock option Activity (Details)	Sep. 30, 2024 $ / shares shares
Outstanding beginning balance (in shares) \| shares	2,788,625
Exercised (in shares) \| shares	(74,321)
Outstanding ending balance (in shares) \| shares	2,714,304
Outstanding beginning balance Weighted Average Exercise Price \| $ / shares	$ 1.93
Exercised Weighted Average Exercise Price \| $ / shares	1.92
Outstanding ending balance Weighted Average Exercise Price \| $ / shares	$ 1.93
Vested Options [Member]
Outstanding beginning balance (in shares) \| shares	2,529,856
Options vesting (in shares) \| shares	417
Exercised (in shares) \| shares	(74,321)
Outstanding ending balance (in shares) \| shares	2,455,952
Outstanding beginning balance Weighted Average Exercise Price \| $ / shares	$ 1.85
Options vesting Weighted Average Exercise Price \| $ / shares	2.19
Exercised Weighted Average Exercise Price \| $ / shares	1.92
Outstanding ending balance Weighted Average Exercise Price \| $ / shares	$ 1.84
Unvested Options [Member]
Outstanding beginning balance (in shares) \| shares	258,769
Options vesting (in shares) \| shares	417
Outstanding ending balance (in shares) \| shares	258,352
Outstanding beginning balance Weighted Average Exercise Price \| $ / shares	$ 2.73
Options vesting Weighted Average Exercise Price \| $ / shares	2.19
Outstanding ending balance Weighted Average Exercise Price \| $ / shares	$ 2.73

Stockholders' Equity - Stock options by exercise price (Details)	3 Months Ended
	Sep. 30, 2024 $ / shares shares
Options Outstanding	2,714,304
Options Exercisable	2,455,952
Range One
Option Exercise Price \| $ / shares	$ 0.70
Options Outstanding	225,000
Remaining Contractual Life (in years)	1 year 2 months 4 days
Options Exercisable	225,000
Range Two
Option Exercise Price \| $ / shares	$ 0.80
Options Outstanding	16,000
Remaining Contractual Life (in years)	10 months 20 days
Options Exercisable	16,000
Range Three
Option Exercise Price \| $ / shares	$ 0.90
Options Outstanding	15,000
Remaining Contractual Life (in years)	10 months 2 days
Options Exercisable	15,000
Range Four
Option Exercise Price \| $ / shares	$ 1.00
Options Outstanding	15,000
Remaining Contractual Life (in years)	5 months 8 days
Options Exercisable	15,000
Range Five
Option Exercise Price \| $ / shares	$ 1.05
Options Outstanding	305,000
Remaining Contractual Life (in years)	1 year 10 months 24 days
Options Exercisable	305,000
Range Six
Option Exercise Price \| $ / shares	$ 1.09
Options Outstanding	40,000
Remaining Contractual Life (in years)	1 year 7 months 24 days
Options Exercisable	40,000
Range Seven
Option Exercise Price \| $ / shares	$ 1.10
Options Outstanding	105,000
Remaining Contractual Life (in years)	9 months
Options Exercisable	105,000
Range Eight
Option Exercise Price \| $ / shares	$ 1.20
Options Outstanding	247,000
Remaining Contractual Life (in years)	3 years 1 month 20 days
Options Exercisable	247,000
Range Nine
Option Exercise Price \| $ / shares	$ 1.59
Options Outstanding	25,000
Remaining Contractual Life (in years)	3 years 7 months 9 days
Options Exercisable	25,000
Range Ten
Option Exercise Price \| $ / shares	$ 2.10
Options Outstanding	238,767
Remaining Contractual Life (in years)	7 years 4 months 9 days
Options Exercisable	238,767
Range Eleven
Option Exercise Price \| $ / shares	$ 2.13
Options Outstanding	211,500
Remaining Contractual Life (in years)	6 years 1 month 17 days
Options Exercisable	211,500
Range Twelve
Option Exercise Price \| $ / shares	$ 2.15
Options Outstanding	200,000
Remaining Contractual Life (in years)	8 years 2 months 8 days
Options Exercisable	200,000
Range Thirteen
Option Exercise Price \| $ / shares	$ 2.17
Options Outstanding	28,000
Remaining Contractual Life (in years)	6 years 7 months 9 days
Options Exercisable	28,000
Range Fourteen
Option Exercise Price \| $ / shares	$ 2.19
Options Outstanding	5,000
Remaining Contractual Life (in years)	7 years 3 months 18 days
Options Exercisable	4,582
Range Fifteen
Option Exercise Price \| $ / shares	$ 2.40
Options Outstanding	284,000
Remaining Contractual Life (in years)	4 years 1 month 13 days
Options Exercisable	284,000
Range Sixteen
Option Exercise Price \| $ / shares	$ 2.43
Options Outstanding	61,250
Remaining Contractual Life (in years)	6 years 8 months 4 days
Options Exercisable	61,250
Range Seventeen
Option Exercise Price \| $ / shares	$ 2.45
Options Outstanding	89,500
Remaining Contractual Life (in years)	5 years 10 months 2 days
Options Exercisable	89,500
Range Eighteen
Option Exercise Price \| $ / shares	$ 2.49
Options Outstanding	73,000
Remaining Contractual Life (in years)	5 years 7 months 9 days
Options Exercisable	73,000
Range Nineteen
Option Exercise Price \| $ / shares	$ 2.50
Options Outstanding	20,000
Remaining Contractual Life (in years)	4 years 7 months 17 days
Options Exercisable	20,000
Range Twenty
Option Exercise Price \| $ / shares	$ 2.64
Options Outstanding	7,353
Remaining Contractual Life (in years)	6 years 10 months 6 days
Options Exercisable	7,353
Range Twenty One
Option Exercise Price \| $ / shares	$ 2.67
Options Outstanding	21,000
Remaining Contractual Life (in years)	6 years 11 months 15 days
Options Exercisable	21,000
Range Twenty Two
Option Exercise Price \| $ / shares	$ 2.73
Options Outstanding	257,934
Remaining Contractual Life (in years)	9 years 2 months 8 days
Range Twenty Three
Option Exercise Price \| $ / shares	$ 2.99
Options Outstanding	8,000
Remaining Contractual Life (in years)	5 years 7 months 13 days
Options Exercisable	8,000
Range Twenty Four
Option Exercise Price \| $ / shares	$ 3.13
Options Outstanding	208,000
Remaining Contractual Life (in years)	5 years 1 month 13 days
Options Exercisable	208,000
Range Twenty Five
Option Exercise Price \| $ / shares	$ 3.50
Options Outstanding	8,000
Remaining Contractual Life (in years)	5 years 4 months 13 days
Options Exercisable	8,000

Stockholders' Equity - Restricted Common Stock Narrative (Details) - USD ($)	3 Months Ended		12 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024
Common stock issued upon exercise of stock options	74,321
Term number of years	5 years
Percentage of All Vested Shares Recipient Is Required To Hold During Employment In Order To Receive Award	75.00%
Fair value of vested restricted common stock	$ 389,133	$ 574,343
Antidilutive securities amount	2,129,523
Minimum [Member]
Expected life (in years)	9 months
Maximum [Member]
Expected life (in years)	2 years 3 months 29 days
Restricted Stock [Member]
Restricted common stock under the long-term equity	250,000		5,589,592
Fair value of restricted common stock	$ 389,133
Fair value of shares vested	532,000		$ 3,152,377
Forfeited, Fair Value	$ (96,925)		$ 580,156
Forfeited, Number of shares	(48,584)		(479,489)
Amount recognized as expense related to stock issuance			$ 6,473,731
Non-vested stock	$ 1,421,141		$ 1,375,199
Balance of non-vested shares	2,129,523		1,957,726
Term number of years	5 years
Restricted stock to employees vested	29,619
Fair value of vested restricted common stock	$ 532,000		$ 8,429,086
Restricted Stock [Member] \| 2017 Plan
Restricted common stock under the long-term equity	250,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period One [Member}
Restricted common stock under the long-term equity	100,000
Vesting percentage	20.00%
Volume Weighted Average Stock Price Per Share	$ 3.00
Restricted stock to employees vested	20,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Two [Member}
Vesting percentage	20.00%
Volume Weighted Average Stock Price Per Share	$ 3.75
Restricted stock to employees vested	20,000
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Three [Member}
Vesting percentage	20.00%
Volume Weighted Average Stock Price Per Share	$ 4.50
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Four [Member}
Vesting percentage	20.00%
Volume Weighted Average Stock Price Per Share	$ 5.25
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Five [Member}
Vesting percentage	20.00%
Volume Weighted Average Stock Price Per Share	$ 6.00
Volume Weighted Average Price (VWAP) of Common Stock over 30-Day Period Six [Member}
Volume Weighted Average Stock Price Per Share	$ 5.00
Restricted stock to employees vested	40,000

Stockholders' Equity - Restricted common stock (Details) - Restricted Stock [Member] - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2024	Jun. 30, 2024
Non-vested, Beginning balance	1,957,726
Granted Number of shares	250,000
Vested, Number of shares	(29,619)
Forfeited, Number of shares	(48,584)	(479,489)
Non-vested, Ending balance	2,129,523	1,957,726
Non-vested, Beginning balance	$ 1,375,199
Granted, Fair Value	532,000
Vested, Fair Value	(389,133)
Forfeited, Fair Value	(96,925)	$ 580,156
Non-vested, Ending balance	$ 1,421,141	$ 1,375,199
Non-vested, Beginning Balance Weighted Average Grant Date Fair Value	$ 1.63
Granted Weighted Average Grant Date Fair Value	2.13
Vested Weighted Average Grant Date Fair Value	2.14
Forfeited Weighted Average Grant Date Fair Value	2.18
Non-vested, Ending Balance Weighted Average Grant Date Fair Value	$ 1.67	$ 1.63

Stockholders' Equity - Repurchases of our common stock (Details) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2024	Mar. 19, 2024
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs	$ 330,774		$ 346,893
Average Price Paid per Share	$ 2.80
Repurchase of common stock	$ 16,119	$ 46,135
Outstanding common stock				$ 82,347
Maximum
Amount of stock authorized for repurchase				$ 750,000
Common Stock [Member]
Total Number of Shares Purchased	5,757	18,603
Repurchase of common stock	$ 6	$ 19
Publicly Announced Plans Or Programs
Share Price				$ 4.00

Acquisitions - Additional Information (Details)				1 Months Ended	3 Months Ended
Acquisitions - Additional Information (Details)	Dec. 01, 2023 USD ($)	Jul. 28, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)	Sep. 30, 2024 USD ($)
Asset Acquisition, Contingent Consideration [Line Items]
Payment for non-refundable deposit for asset acquisition			$ 297,450	€ 300,000
Contingent consideration for customers					$ 64,578
Asset acquisition, contingent consideration, liability, noncurrent					33,353
Contingent earnout fair value					0
Payment of bonus amount					$ 31,018
Estimated average useful life					10 years
Scite
Asset Acquisition, Contingent Consideration [Line Items]
Percentage of ownership interest acquired	100.00%
Initial payment	$ 7,217,000
Purchase consideration, net of cash acquired	21,135,000
Holdback cash paid	175,000
Cash	6,549,000
Contingent earnout fair value	$ 7,200,000				$ 12,200,000
Resolute AI
Asset Acquisition, Contingent Consideration [Line Items]
Percentage of ownership interest acquired		100.00%
Initial payment		$ 2,774,000
Purchase consideration, net of cash acquired		4,766,000
Holdback cash paid		125,000
Enterprise value		3,400,000
Contingent earnout fair value		$ 1,800,000
Multiplying factor for calculation of earnout		3.5

Acquisitions - Assets and liabilities assumed (Details) - USD ($)			3 Months Ended
	Dec. 01, 2023	Jul. 28, 2023	Sep. 30, 2024	Jun. 30, 2024
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Net identifiable intangible assets			$ 8,117,222
Goodwill			$ 16,345,888	$ 16,315,888
Resolute AI
Fair value of consideration
Cash		$ 2,774,000
Holdback cash paid		125,000
Contingent earn-out		1,867,000
Total purchase price		4,766,000
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Cash and cash equivalents		59,000
Accounts receivable		162,000
Prepaid expenses		43,000
Accounts payable and accrued expenses		(33,000)
Deferred revenue		(649,000)
Other current liabilities		(60,000)
Net tangible assets		(478,000)
Net identifiable intangible assets		2,100,000
Goodwill		3,144,000
Fair value of net assets acquired		4,766,000
Resolute AI \| Developed technology
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Net identifiable intangible assets		2,000,000
Resolute AI \| Customer relationships
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Net identifiable intangible assets		$ 100,000
Scite
Fair value of consideration
Cash	$ 7,217,000
Holdback cash paid	175,000
Common Stock (2,729,014 shares at $2.40 per share)	6,549,000
Contingent earn-out	7,194,000
Total purchase price	21,135,000
Common stock			2,729,014
Common stock per share			$ 2.40
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Accounts receivable	109,000
Deferred revenue	(997,000)
Other current liabilities	(18,000)
Net tangible assets	(906,000)
Net identifiable intangible assets	8,870,000
Goodwill	13,171,000		$ 13,171,486	$ 13,171,486
Fair value of net assets acquired	21,135,000
Scite \| Developed technology
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Net identifiable intangible assets	8,800,000
Scite \| Customer relationships
Allocation of the consideration to the fair value of assets acquired and liabilities assumed:
Net identifiable intangible assets	$ 70,000

Acquisitions - Pro forma operating results (Details) - USD ($)	3 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Acquisitions
Revenue	$ 12,044,482	$ 10,800,908
Cost of revenue	6,278,606	6,090,058
Gross profit	5,765,876	4,710,850
Total operating expenses	5,119,185	5,673,375
Loss from operations	646,691	(962,525)
Other income (expense)	68,525	141,313
Income (loss) from operations before provision for income taxes	715,216	(821,212)
Provision for income taxes	(46,212)	(29,402)
Pro Forma Net income (loss)	$ 669,004	$ (850,614)
Pro Forma Net income (loss) per weighted average share, basic (in dollars per share)	$ 0.02	$ (0.03)
Pro Forma Net income (loss) per weighted average share, diluted (in dollars per share)	$ 0.02	$ (0.03)

Subsequent Events (Details) - shares		3 Months Ended	12 Months Ended
Subsequent Events (Details) - shares	Nov. 12, 2024	Sep. 30, 2024	Jun. 30, 2024
Subsequent Event [Line Items]
Common stock issued upon exercise of stock options		74,321
Restricted Common Stock
Subsequent Event [Line Items]
Restricted common stock under the long-term equity		250,000	5,589,592
Subsequent Event \| Restricted Common Stock
Subsequent Event [Line Items]
Restricted common stock under the long-term equity	340,000